<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001942.pub5" GROUP_ID="NEUROMUSC" ID="947199091510271868" MERGED_FROM="" MODIFIED="2016-07-12 17:44:55 +0100" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;7.6.01&lt;br&gt;LD inserted links to all references in text. Two reference details missing: Taverner &amp;amp; Akpinar. RAS asked to provide details.&lt;br&gt;8.6.01&lt;br&gt;RAS provided details of Taverner but title missing. LD inserted akpinar ref. Taverner title inserted 12/06/01 by LD&lt;/p&gt;&lt;p&gt;Need to discuss order of authors with FS&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2016-07-12 17:44:08 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="006" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2016-07-12 17:44:41 +0100" MODIFIED_BY="Ruth Brassington">
<TITLE MODIFIED="2016-07-10 16:33:41 +0100" MODIFIED_BY="Anne Lawson">Corticosteroids for Bell's palsy (idiopathic facial paralysis)</TITLE>
<CONTACT MODIFIED="2016-07-12 17:44:41 +0100" MODIFIED_BY="Ruth Brassington"><PERSON ID="z1305211200234164391015338304569" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Vishnu</FIRST_NAME><MIDDLE_INITIALS>B</MIDDLE_INITIALS><LAST_NAME>Madhok</LAST_NAME><SUFFIX>MBChB, MRCGP</SUFFIX><POSITION>General Practitioner</POSITION><EMAIL_1>vishnumadhok@nhs.net</EMAIL_1><EMAIL_2>vmadhok@doctors.org.uk</EMAIL_2><URL>http://medicine.dundee.ac.uk/staff-member/dr-vishnu-b-madhok</URL><MOBILE_PHONE>07703473808</MOBILE_PHONE><ADDRESS><ORGANISATION>Park House Surgery</ORGANISATION><ADDRESS_1>Park Street</ADDRESS_1><CITY>Bagshot</CITY><ZIP>GU19 5AQ</ZIP><REGION>Surrey</REGION><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-07-12 17:44:41 +0100" MODIFIED_BY="Ruth Brassington"><PERSON ID="z1305211200234164391015338304569" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Vishnu</FIRST_NAME><MIDDLE_INITIALS>B</MIDDLE_INITIALS><LAST_NAME>Madhok</LAST_NAME><SUFFIX>MBChB, MRCGP</SUFFIX><POSITION>General Practitioner</POSITION><EMAIL_1>vishnumadhok@nhs.net</EMAIL_1><EMAIL_2>vmadhok@doctors.org.uk</EMAIL_2><URL>http://medicine.dundee.ac.uk/staff-member/dr-vishnu-b-madhok</URL><MOBILE_PHONE>07703473808</MOBILE_PHONE><ADDRESS><ORGANISATION>Park House Surgery</ORGANISATION><ADDRESS_1>Park Street</ADDRESS_1><CITY>Bagshot</CITY><ZIP>GU19 5AQ</ZIP><REGION>Surrey</REGION><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="z1309111008522937273859629128343" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ildiko</FIRST_NAME><LAST_NAME>Gagyor</LAST_NAME><POSITION>Academic GP</POSITION><EMAIL_1>Ildiko.Gagyor@medizin.uni-goettingen.de</EMAIL_1><MOBILE_PHONE>+49(0)175 531 4779</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of General Practice/Family Medicine</DEPARTMENT><ORGANISATION>University of Göttingen</ORGANISATION><ADDRESS_1>Humboldtalle 38</ADDRESS_1><CITY>Göttingen</CITY><ZIP>37073</ZIP><REGION>Lower Saxony</REGION><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+495513914226</PHONE_1></ADDRESS></PERSON><PERSON ID="08C0070D82E26AA200C1C7C47268A583" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Fergus</FIRST_NAME><LAST_NAME>Daly</LAST_NAME><POSITION>Dr F Daly Biostatistics Team Lead</POSITION><ADDRESS><ORGANISATION>Frontier Science (Scotland) Ltd</ORGANISATION><ADDRESS_1>Grampian View Kincraig,</ADDRESS_1><CITY>Kingussie</CITY><ZIP>PH21 1NA</ZIP><REGION>Inverness-shire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>1540 651012</PHONE_1></ADDRESS></PERSON><PERSON ID="z1309040956374904322560980402530" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Dhruvashree</FIRST_NAME><LAST_NAME>Somasundara</LAST_NAME><POSITION>General Practice Registrar</POSITION><EMAIL_1>d.somasundara@nhs.net</EMAIL_1><ADDRESS><DEPARTMENT>Centre for Primary Care and Population Research, Division of Clinical and Population Sciences and Education</DEPARTMENT><ORGANISATION>University of Dundee</ORGANISATION><ADDRESS_1>The Mackenzie Building</ADDRESS_1><ADDRESS_2>Kirsty Semple Way</ADDRESS_2><CITY>Dundee</CITY><ZIP>DD2 4BF</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="z1310220943237134598852299548582" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Michael</FIRST_NAME><LAST_NAME>Sullivan</LAST_NAME><POSITION>MSc Student</POSITION><EMAIL_1>sullivanmk@doctors.org.uk</EMAIL_1><EMAIL_2>s1371258@ed.ac.uk</EMAIL_2><MOBILE_PHONE>07763 109784</MOBILE_PHONE><ADDRESS><DEPARTMENT>School of Clinical Sciences</DEPARTMENT><ORGANISATION>University of Edinburgh</ORGANISATION><ADDRESS_1>Old College</ADDRESS_1><ADDRESS_2>South Bridge</ADDRESS_2><CITY>Edinburgh</CITY><ZIP>EH8 9YL</ZIP><REGION>Lothian</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>0131 650 1000</PHONE_1><FAX_1>0131 650 2147</FAX_1></ADDRESS></PERSON><PERSON ID="z1401151148553872165321071188561" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Fiona</FIRST_NAME><LAST_NAME>Gammie</LAST_NAME><POSITION>Clinical Research Nurse</POSITION><EMAIL_1>fiona.gammie@gmail.com</EMAIL_1><EMAIL_2>f.gammie@abdn.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>Centre for Primary Care and Population Research, Division of Clinical and Population Sciences and Education</DEPARTMENT><ORGANISATION>University of Dundee</ORGANISATION><ADDRESS_1>Mackenzie Building, Rm FF2</ADDRESS_1><ADDRESS_2>Ninewells Hospital and Medical School</ADDRESS_2><CITY>Dundee</CITY><ZIP>DD2 4BF</ZIP><REGION>Scotland</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>01382 383800 ext 83957</PHONE_1></ADDRESS></PERSON><PERSON ID="8188" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Frank</FIRST_NAME><LAST_NAME>Sullivan</LAST_NAME><POSITION>Gordon F. Cheesbrough Chair in Family &amp; Community Medicine, Director of UTOPIAN the University of Toronto Practice Based Research Network</POSITION><EMAIL_1>utopian.director@utoronto.ca</EMAIL_1><EMAIL_2>frank.sullivan@nygh.on.ca</EMAIL_2><ADDRESS><DEPARTMENT>Department of Family and Community Medicine</DEPARTMENT><ORGANISATION>North York General Hospital, University of Toronto</ORGANISATION><ADDRESS_1>500 University Avenue, 5th Floor</ADDRESS_1><CITY>Toronto</CITY><ZIP>M5G 1V7</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-07-12 09:06:53 +0100" MODIFIED_BY="Anne Lawson">
<UP_TO_DATE>
<DATE DAY="4" MONTH="3" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="4" MONTH="3" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="4" MONTH="3" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="7" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-07-04 13:58:40 +0100" MODIFIED_BY="Ruth  Brassington">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-07-04 13:58:40 +0100" MODIFIED_BY="Ruth  Brassington">
<DATE DAY="4" MONTH="7" YEAR="2016"/>
<DESCRIPTION>
<P>New author team. One new trial was found, with no change to previous conclusions. We made the following corrections and revisions:</P>
<UL>
<LI>more detailed documentation of methods and additional sections to comply with current standards</LI>
<LI>amendments and corrections in the results section</LI>
<LI>inclusion of additional study data in our primary analysis, which changed the RR for incomplete recovery from 0.71 (95% CI 0.61 to 0.83) to 0.63 (95% CI 0.50 to 0.80)</LI>
<LI>we largely presented available data analyses, reporting intention-to-treat data only when trialists used this approach</LI>
<LI>removal of comparisons involving antiviral co-medication, which are analysed in a separate Cochrane review</LI>
<LI>inclusion of an analysis of adverse events</LI>
<LI>inclusion of a 'Summary of findings' table and of comments on the quality of evidence in the text of the review</LI>
</UL>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-07-04 13:58:15 +0100" MODIFIED_BY="Ruth  Brassington">
<DATE DAY="4" MONTH="3" YEAR="2016"/>
<DESCRIPTION>
<P>Searches updated and integrated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-01-13 09:56:07 +0000" MODIFIED_BY="Ruth Brassington">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2014-01-13 09:56:07 +0000" MODIFIED_BY="Ruth Brassington">
<DATE DAY="25" MONTH="2" YEAR="2009"/>
<DESCRIPTION>
<P>New trials have been added leading to a substantial change in the conclusion of the review</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-01-18 15:43:06 +0000" MODIFIED_BY="Ruth Brassington">
<DATE DAY="16" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="23" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-02-25 11:24:33 +0000" MODIFIED_BY="Kate Jewitt">
<DATE DAY="28" MONTH="2" YEAR="2006"/>
<DESCRIPTION>
<P>February 2006<BR/>We updated the search of the Cochrane Neuromuscular Disease Group specialised register (November 2005), MEDLINE (January 1966 to November 2005), EMBASE (January 1980 to November 2005) and LILACS (January 1982 to November 2005). No new randomised controlled trials were found.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2016-07-12 12:39:37 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2016-07-12 12:39:37 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2016-07-12 12:39:37 +0100" MODIFIED_BY="[Empty name]">
<NAME>New source of support</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-07-12 17:43:40 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-07-12 12:46:55 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-02-04 13:25:34 +0000" MODIFIED_BY="Ruth Brassington">Corticosteroids for Bell's palsy</TITLE>
<SUMMARY_BODY MODIFIED="2016-07-12 12:46:55 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;update at the end also (VM)&lt;/p&gt;" NOTES_MODIFIED="2016-07-12 12:46:55 +0100" NOTES_MODIFIED_BY="[Empty name]">
<P>
<B>Review question</B>
</P>
<P>What are the effects of corticosteroids on Bell's palsy?</P>
<P>
<B>Background</B>
</P>
<P>Bell's palsy is a paralysis or weakness of muscles in the face, usually on one side, with no certain cause. Symptoms usually recover, although not always. Reducing inflammation of the facial nerve using corticosteroid medicines (steroids) is thought to limit nerve damage. This is an update of a review first published in 2002 and last updated in 2010.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We identified seven clinical trials involving 895 people with one-sided mild, moderate or severe Bell's palsy of unknown cause. All of these trials reported rates of incomplete recovery (the proportion of people left with facial weakness) and we were able to combine the results. People in the studies were aged from 2 to 84 years. They were treated with corticosteroids or placebo (inactive treatment), either alone or in combination with other therapies. One trial only involved children, from 24 months to 74 months old. The duration of the included studies for adults and children ranged from 157 days to 12 months.</P>
<P>
<B>Key results and quality of the evidence</B>
</P>
<P>
<I>Incomplete recovery</I>
</P>
<P>According to moderate quality to high quality evidence, corticosteroids reduced the number of people left with facial weakness after Bell's palsy compared to placebo (a pretend medicine). This finding was based on data from seven studies involving 895 participants with Bell's palsy of varying degrees of severity. We calculated that to stop one person from being left with facial weakness, 10 people need to be treated.</P>
<P>Five studies provided data on long-term after-effects of Bell's palsy following treatment. Two of the studies (75 participants) looked at persistent effects on facial appearance after six months or more. The effect was nearly the same for corticosteroids and placebo, showing that participants who had corticosteroids benefited slightly, although this evidence was low quality. Data from three studies (485 participants) showed clearly that people who received corticosteroids developed less motor synkinesis (unwanted facial movements) and crocodile tears (watery eyes when eating or chewing), compared with people who received placebo alone. This finding was based on moderate-quality evidence.</P>
<P>
<I>Side effects</I>
</P>
<P>Three studies reported that no side effects could be attributed to corticosteroid treatment. Based on moderate-quality evidence from three studies (715 participants), numbers experiencing side effects were similar with corticosteroids and placebo.</P>
<P>The evidence is current to March 2016.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-07-12 13:56:34 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2016-07-12 12:47:16 +0100" MODIFIED_BY="[Empty name]">
<P>Inflammation and oedema of the facial nerve are implicated in causing Bell's palsy. Corticosteroids have a potent anti-inflammatory action that should minimise nerve damage. This is an update of a review first published in 2002 and last updated in 2010.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-06-09 23:19:29 +0100" MODIFIED_BY="Ruth  Brassington">
<P>To determine the effectiveness and safety of corticosteroid therapy in people with Bell's palsy. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-06-29 09:35:54 +0100" MODIFIED_BY="Ruth  Brassington">
<P>On 4 March 2016, we searched the Cochrane Neuromuscular Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and LILACS. We reviewed the bibliographies of the randomised trials and contacted known experts in the field to identify additional published or unpublished trials. We also searched clinical trials registries for ongoing trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-03-03 09:08:16 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Randomised trials and quasi-randomised trials comparing different routes of administration and dosage schemes of corticosteroid or adrenocorticotrophic hormone therapy versus a control group receiving no therapy considered effective for this condition, unless the same therapy was given in a similar way to the experimental group. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-07-12 13:56:34 +0100" MODIFIED_BY="[Empty name]">
<P>We used standard Cochrane methodology. The main outcome of interest was incomplete recovery of facial motor function (i.e. residual facial weakness). Secondary outcomes were cosmetically disabling persistent sequelae, development of motor synkinesis or autonomic dysfunction (i.e. hemifacial spasm, crocodile tears) and adverse effects of corticosteroid therapy manifested during follow-up.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-07-12 12:47:47 +0100" MODIFIED_BY="[Empty name]">
<P>We identified seven trials, with 895 evaluable participants for this review. All provided data suitable for the primary outcome meta-analysis. One of the trials was new since the last version of this Cochrane systematic review. Risk of bias in the older, smaller studies included some unclear- or high-risk assessments, whereas we deemed the larger studies at low risk of bias. Overall, 79/452 (17%) participants allocated to corticosteroids had incomplete recovery of facial motor function six months or more after randomisation; significantly fewer than the 125/447 (28%) in the control group (risk ratio (RR) 0.63, 95% confidence interval (CI) 0.50 to 0.80, seven trials, n = 895). The number of people who need to be treated with corticosteroids to avoid one incomplete recovery was 10 (95% CI 6 to 20). The reduction in the proportion of participants with cosmetically disabling sequelae six months after randomisation was very similar in the corticosteroid and placebo groups (RR 0.96, 95% CI 0.40 to 2.29, two trials, n = 75, low-quality evidence). However, there was a significant reduction in motor synkinesis during follow-up in participants receiving corticosteroids (RR 0.64, 95% CI 0.45 to 0.91, three trials, n = 485, moderate-quality evidence). Three studies explicitly recorded the absence of adverse effects attributable to corticosteroids. One trial reported that three participants receiving prednisolone had temporary sleep disturbances and two trials gave a detailed account of adverse effects occurring in 93 participants, all non-serious; the combined analysis of data from these three trials found no significant difference in adverse effect rates between people receiving corticosteroids and people receiving placebo (RR 1.04, 95% CI 0.71 to 1.51, n = 715).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-07-12 13:56:21 +0100" MODIFIED_BY="[Empty name]">
<P>The available moderate- to high-quality evidence from randomised controlled trials showed significant benefit from treating Bell's palsy with corticosteroids.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-07-12 17:43:40 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2016-07-12 17:04:01 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2016-07-12 12:47:04 +0100" MODIFIED_BY="[Empty name]">
<P>Bell's palsy is an acute, generally unilateral, paralysis or weakness of facial musculature consistent with peripheral facial nerve dysfunction, of no detectable cause (<LINK REF="REF-Niparko-1993" TYPE="REFERENCE">Niparko 1993</LINK>). Additional symptoms frequently include pain around or behind the ear sometimes extending into the occipital or cervical region. Impaired tolerance to ordinary levels of noise and disturbed sense of taste on the same side may also be present (<LINK REF="REF-Burgess-1984" TYPE="REFERENCE">Burgess 1984</LINK>).</P>
<P>Epidemiological studies have reported an annual incidence of 23 to 25 per 100,000 per year (<LINK REF="REF-Martyn-1997" TYPE="REFERENCE">Martyn 1997</LINK>; <LINK REF="REF-Victor-1994" TYPE="REFERENCE">Victor 1994</LINK>), but one study using a general practitioner (GP) database has suggested it may be even higher at 37 per 100,000 per year (<LINK REF="REF-Morales-2013" TYPE="REFERENCE">Morales 2013</LINK>). Bell's palsy affects men and women more or less equally. Until recently was thought to be most common in the 30- to 45-year age group (<LINK REF="REF-Bateman-1992" TYPE="REFERENCE">Bateman 1992</LINK>; <LINK REF="REF-Brandenberg-1993" TYPE="REFERENCE">Brandenberg 1993</LINK>; <LINK REF="REF-Katusic-1986" TYPE="REFERENCE">Katusic 1986</LINK>; <LINK REF="REF-Peitersen-1982" TYPE="REFERENCE">Peitersen 1982</LINK>; <LINK REF="REF-Peitersen-2002" TYPE="REFERENCE">Peitersen 2002</LINK>; <LINK REF="REF-Yanagihara-1988" TYPE="REFERENCE">Yanagihara 1988</LINK>), although the one more recent primary care database study suggested a peak in people over 70 years of age (<LINK REF="REF-Morales-2013" TYPE="REFERENCE">Morales 2013</LINK>). The condition presents disproportionately among pregnant women and people who have diabetes, influenza, a cold, or some other upper respiratory ailment. On average, every year a British GP will see one or two people who have developed the condition. Both sides of the face are affected equally often (<LINK REF="REF-Prescott-1988" TYPE="REFERENCE">Prescott 1988</LINK>).</P>
<P>The aetiology of Bell's palsy is still debated. A viral infection, vascular ischaemia, autoimmune inflammatory disorders and heredity have been proposed as underlying causes (<LINK REF="REF-Adour-1982" TYPE="REFERENCE">Adour 1982</LINK>; <LINK REF="REF-Burgess-1984" TYPE="REFERENCE">Burgess 1984</LINK>; <LINK REF="REF-Lackner-2010" TYPE="REFERENCE">Lackner 2010</LINK>). A viral aetiology has gained popularity since the isolation of herpes simplex virus-1 (HSV-1) genome from the facial nerve endoneurial fluid of people with Bell's palsy (<LINK REF="REF-Lackner-2010" TYPE="REFERENCE">Lackner 2010</LINK>; <LINK REF="REF-Murakami-1996" TYPE="REFERENCE">Murakami 1996</LINK>). The prognosis is on the whole favourable. One of the largest series of people with Bell's palsy including those who were not receiving specific therapy, showed that 85% of people with Bell's palsy began to recover within three weeks of onset (<LINK REF="REF-Peitersen-1982" TYPE="REFERENCE">Peitersen 1982</LINK>). For the remaining 15%, partial recovery occurred three to six months later. The same series showed that normal facial expression reappeared in 71% of cases, 13% had insignificant sequelae, and the remaining 16% had permanently diminished function with aberrant innervation (expressed as motor synkinesis or autonomic dysfunction) and post-paralytic spasms.</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-07-12 12:45:40 +0100" MODIFIED_BY="[Empty name]">
<P>The treatment of Bell's palsy used to be highly controversial. Corticosteroids were the treatment of choice, based mainly on non-randomised comparisons (<LINK REF="REF-Adour-1972" TYPE="REFERENCE">Adour 1972</LINK>). The authors of numerous clinical series both espoused and condemned corticosteroid therapy with, what appeared to them, equally convincing arguments (<LINK REF="REF-Burgess-1984" TYPE="REFERENCE">Burgess 1984</LINK>). Four systematic reviews found a significant trend favouring corticosteroid treatment in improving the recovery of facial motor function (<LINK REF="REF-de-Almeida-2009" TYPE="REFERENCE">de Almeida 2009</LINK>; <LINK REF="REF-Grogan-2001" TYPE="REFERENCE">Grogan 2001</LINK>; <LINK REF="REF-Ramsey-2000" TYPE="REFERENCE">Ramsey 2000</LINK>; <LINK REF="REF-Williamson-1996" TYPE="REFERENCE">Williamson 1996</LINK>). However, their conclusions were affected by including trials of poor quality in the pooled estimate. <LINK REF="REF-de-Almeida-2009" TYPE="REFERENCE">de Almeida 2009</LINK>, a state-of-the-art, high-quality systematic review, differed from our methodology in the way they collected data, in the inclusion of a non-randomised trial that we excluded (<LINK REF="STD-Martinez-1990" TYPE="STUDY">Martinez 1990</LINK>), and in the exclusion of a trial that we included in our analysis (<LINK REF="STD-Taverner-1954" TYPE="STUDY">Taverner 1954</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2016-07-12 17:04:01 +0100" MODIFIED_BY="[Empty name]">
<P>Corticosteroids are known to have an anti-inflammatory mode of action, which reduces oedema and inflammation of the facial nerve in the acute presentation of Bell's palsy.</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-07-12 12:45:50 +0100" MODIFIED_BY="[Empty name]">
<P>The purpose of this systematic review was to collect and analyse the available evidence from randomised controlled trials concerning the use of corticosteroids for improving the outcome of people with Bell's palsy. This is an update of a review first published in 2002 and last updated in 2010. We updated the review to assess the quality of the evidence regarding the benefit of corticosteroids in Bell's palsy using current methodology, integrate any new evidence and to determine whether further research would be likely to change the estimate of effect or its certainty.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-07-12 17:43:14 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;The wording of the 'Objectives' should be short and to the point so I have deleted some of the text as the first sentence is adequate. It should be identical to the Objectives in the Abstract.&lt;/p&gt;" NOTES_MODIFIED="2016-07-12 17:43:14 +0100" NOTES_MODIFIED_BY="[Empty name]">
<P>To determine the effectiveness and safety of corticosteroid therapy in people with Bell's palsy.</P>
<P/>
<P/>
<P/>
</OBJECTIVES>
<METHODS MODIFIED="2016-07-12 17:43:14 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2016-07-12 17:43:14 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2016-07-12 12:43:16 +0100" MODIFIED_BY="[Empty name]">
<P>Trials of the use of corticosteroid therapy for the treatment of recent-onset Bell's palsy in which an attempt had apparently been made to conduct a randomised or quasi-randomised comparison between corticosteroid therapy and a placebo, or open control group. As in the previous version of the review, we used study quality as an exclusion criteria excluding trials with a high risk of bias in several domains.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-07-12 17:43:14 +0100" MODIFIED_BY="[Empty name]">
<P>Participants of any age with clinically diagnosed Bell's palsy, irrespective of the time of evolution of symptoms. We included all participants considered to have Bell's palsy or acute idiopathic facial nerve paralysis by the study authors, irrespective of the ancillary studies they performed to rule out other causes of facial paralysis. We included in the analysis all participants considered eligible by the authors of the studies, irrespective of associated conditions.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-07-12 17:04:09 +0100" MODIFIED_BY="[Empty name]">
<P>We included trials using any corticosteroid or adrenocorticotrophic hormone therapy, irrespective of the route of administration (oral or parenteral) and length of therapy. We excluded trials in which a drug considered 'effective' for this condition was given to the control group, unless it was given in a similar way to the experimental group. The exception was studies in which control and treatment groups received concomitant antiviral therapy; these are not included in this review, but in the updated Cochrane review 'Antiviral treatment for Bell's palsy (idiopathic facial paralysis)' (<LINK REF="REF-Gagyor-2015" TYPE="REFERENCE">Gagyor 2015</LINK>).</P>
<P>We excluded trials comparing different types of corticosteroids or different dosage schemes, unless the trial included a placebo group.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-07-12 17:04:10 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-07-11 21:00:01 +0100" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Incomplete recovery of facial motor function six months or more after randomisation.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-07-12 17:04:10 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Cosmetically disabling persistent sequelae of facial paralysis (poor recovery of facial motor function as defined by the authors of the studies) six months or more after randomisation.</LI>
<LI>Motor synkinesis or autonomic dysfunction during follow-up (including facial spasm, motor synkinesis and crocodile tears).</LI>
<LI>Adverse effects attributable to the use of corticosteroids.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-07-12 17:04:12 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2016-07-12 17:04:12 +0100" MODIFIED_BY="[Empty name]">
<P>On 4 March 2016, we searched the Cochrane Neuromuscular Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL in the <I>Cochrane Register of Studies Online</I>), MEDLINE (January 1966 to February 2016), EMBASE (January 1980 to February 2016) and LILACS (January 1982 to February 2016). The detailed search strategies are in the appendices: Cochrane Neuromuscular Specialised Register (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), CENTRAL (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), MEDLINE (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), EMBASE (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>) and LILACS (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>).</P>
<P>On 21 June 2016, we searched <A HREF="https://clinicaltrials.gov/">ClinicalTrials.gov</A> and the World Health Organization International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://apps.who.int/trialsearch/">who.int/trialsearch/</A>) for ongoing studies. We searched both using the term "Bell's Palsy".</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-01-25 23:28:40 +0000" MODIFIED_BY="Ruth Brassington">
<P>We reviewed the bibliographies of the randomised trials and contacted the study authors and known experts in the field to identify additional published or unpublished data.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-07-12 17:04:29 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2016-07-12 12:16:25 +0100" MODIFIED_BY="[Empty name]">
<P>Six review authors scrutinised published and unpublished papers retrieved by the literature searches to select papers for inclusion. At least two review authors independently assessed each paper for relevance, eligibility and quality. There were no disagreements about inclusion. We applied no language limitations.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-07-12 17:04:15 +0100" MODIFIED_BY="[Empty name]">
<P>Review authors collected and analysed data in pairs (FG and VM, DS and MS, IG and FS). We collected data on the following.</P>
<UL>
<LI>Methods: study design, study duration, number of study centres and location, study setting, withdrawals, and date of study.</LI>
<LI>Participants: number (n), mean age, age range, gender, severity of condition, diagnostic criteria, baseline characteristics, inclusion criteria and exclusion criteria.</LI>
<LI>Interventions: intervention, comparison, concomitant medications.</LI>
<LI>Outcomes: primary and secondary outcomes specified and collected, and time points reported; definition of recovery status.</LI>
<LI>Notes: funding for trial and notable conflicts of interest of trial authors.</LI>
</UL>
<P>All six review authors had a selection of papers to read, review for quality and extract data from. At least two review authors assessed each trial. All review authors agreed data extraction.</P>
<P>Two review authors (IG and VM) inputted data into Review Manager 5 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-07-12 17:04:16 +0100" MODIFIED_BY="[Empty name]">
<P>IG completed the 'Risk of bias' table. FS and FD individually reviewed the 'Risk of bias' assessments. We assessed bias by scoring studies as at high, low or unclear risk of bias using methods described in the <I>Cochrane Handbook for Systematic Reviews of Interventio</I>ns (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-07-12 12:42:48 +0100" MODIFIED_BY="[Empty name]">
<P>When comparing studies using different symptom scores to assess outcomes, we used the House-Brackmann scale when available as this was the most widely used or had comparisons to other scales available. When assessing adverse effects, we reported the number of participants affected, as opposed to the number of events, to facilitate data comparison.</P>
<P>We used dichotomous outcomes and we analysed data as risk ratios (RR) with a corresponding 95% confidence interval (CI). We calculated a treatment effect using the Mantel-Haenszel method (<LINK REF="REF-Egger-2007" TYPE="REFERENCE">Egger 2007</LINK>).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-07-12 12:50:39 +0100" MODIFIED_BY="[Empty name]">
<P>Where a single trial included multiple trial arms, we included only arms relevant to this review. If two comparisons (e.g. drug A versus placebo and drug B versus placebo) had been combined in the same meta-analysis, our preference would be to combine groups to create a single comparison if appropriate, or otherwise use one of the other approaches described in Chapter 16 of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-07-12 17:04:20 +0100" MODIFIED_BY="[Empty name]">
<P>One of the trial authors, who is also a review author (FS), provided unpublished trial data. We also contacted a previous study team member (P Lockhart) for additional information on other studies and received a response. We either extracted the number of participants who completed a treatment originally allocated and the number with the outcome, and considered the potential effect of missing data when presenting results, or reported intention-to-treat analyses as presented in trial reports. Where data were unavailable we contacted the original authors, when there was no response, we calculated the numbers from the rates and percentages presented in the papers. We undertook no sensitivity analyses for missing values. For some trials, we calculated either number in the analysis or the number experiencing an event using the percentage experiencing an event.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-07-12 12:16:55 +0100" MODIFIED_BY="[Empty name]">
<P>We used the I<SUP>2</SUP> statistic to measure heterogeneity among the trials in each analysis, using the thresholds in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> as guidance (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>):</P>
<UL>
<LI>0% to 40%: might not be important;</LI>
<LI>30% to 60%: may represent moderate heterogeneity;</LI>
<LI>50% to 90%: may represent substantial heterogeneity;</LI>
<LI>75% to 100%: considerable heterogeneity.</LI>
</UL>
<P>We interpreted the I<SUP>2</SUP> statistic in the context of its CI, the Chi<SUP>2</SUP> test, P value and the size of the effect.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-07-12 17:04:21 +0100" MODIFIED_BY="[Empty name]">
<P>Since we were unable to pool more than 10 trials, we could not create a funnel plot to explore possible small-study biases.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-07-12 17:04:29 +0100" MODIFIED_BY="[Empty name]">
<P>We used a fixed-effect model for our analysis and performed a sensitivity analysis with a random-effects model.</P>
<P>If the review had included more than one comparison that could not be included in the same analysis, we would have reported the results for each comparison separately.</P>
<P>Throughout we have utilised the following notations: </P>
<P>OS: corticosteroid treatment alone</P>
<P>OO: placebo or no treatment only</P>
<P>Using these notations, we conducted the following comparison: OS versus OO.</P>
<SUBSECTION>
<HEADING LEVEL="3">'Summary of findings' table</HEADING>
<P>At this update, we added a 'Summary of findings' table. We used the following outcomes: incomplete recovery, cosmetically disabling persistent sequelae six months or more after randomisation, motor synkinesis and crocodile tears, and adverse effects.</P>
<P>Under the GRADE approach, the levels of quality of evidence are high, moderate, low or very low. Assessors start at high quality and may downgrade the evidence for the pre-specified outcomes depending on five GRADE considerations, which are: study limitations, consistency of effect, imprecision, indirectness and publication bias. We used methods and recommendations described in Section 8.5 and Chapter 12 of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We used GRADEpro software (<LINK REF="REF-GRADEpro-2008" TYPE="REFERENCE">GRADEpro 2008</LINK>). We have justified all decisions to downgrade or upgrade the quality of studies using footnotes and have made comments to aid readers' understanding of the review where necessary.</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-04-20 18:40:11 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We did not undertake any subgroup analyses for this review. The protocol detailed possible subgroup analyses, although none were appropriate for the included studies.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-07-11 21:00:18 +0100" MODIFIED_BY="Anne Lawson">
<P>We carried out the following sensitivity analyses.</P>
<UL>
<LI>Repeated the analyses excluding smaller and underpowered studies.</LI>
<LI>Repeated the analyses excluding studies with short-term follow-up (less than nine months).</LI>
</UL>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-07-12 17:05:01 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2016-07-12 17:04:46 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2016-07-12 17:04:33 +0100" MODIFIED_BY="[Empty name]">
<P>In the updated searches for this review, we found 59 references in the Cochrane Neuromuscular Specialised Register, 81 in CENTRAL, 818 in MEDLINE, 117 in EMBASE and 15 in LILACS.</P>
<P>There were seven completed randomised controlled trials comparing corticosteroids with no active control when this review was first written. In subsequent updates, review authors identified five other potentially relevant trials (<LINK REF="STD-Austin-1993" TYPE="STUDY">Austin 1993</LINK>; <LINK REF="STD-Bento-1991" TYPE="STUDY">Bento 1991</LINK>; <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>; <LINK REF="STD-Lagalla-2002" TYPE="STUDY">Lagalla 2002</LINK>; <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>).</P>
<P>In all, seven trials including 895 evaluable participants met our inclusion criteria (<LINK REF="STD-Austin-1993" TYPE="STUDY">Austin 1993</LINK>; <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>; <LINK REF="STD-Lagalla-2002" TYPE="STUDY">Lagalla 2002</LINK>; <LINK REF="STD-May-1976" TYPE="STUDY">May 1976</LINK>; <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>; <LINK REF="STD-Taverner-1954" TYPE="STUDY">Taverner 1954</LINK>; <LINK REF="STD-Unuvar-1999" TYPE="STUDY">Unuvar 1999</LINK>).</P>
<P>See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for a flow chart illustrating the study selection process for this update.</P>
<P>The previous update of this review, <LINK REF="REF-Salinas-2010" TYPE="REFERENCE">Salinas 2010</LINK>, listed seven excluded studies (<LINK REF="STD-Akpinar-1979" TYPE="STUDY">Akpinar 1979</LINK>; <LINK REF="STD-Austin-1993" TYPE="STUDY">Austin 1993</LINK>; <LINK REF="STD-Bento-1991" TYPE="STUDY">Bento 1991</LINK>; Bento 1994; <LINK REF="STD-Brown-1982" TYPE="STUDY">Brown 1982</LINK>; <LINK REF="STD-Martinez-1990" TYPE="STUDY">Martinez 1990</LINK>; <LINK REF="STD-Wolf-1978" TYPE="STUDY">Wolf 1978</LINK>). We have linked two references previously listed as separate trials (Bento 1991 and Bento 1994) under one trial identifier in this update (<LINK REF="STD-Bento-1991" TYPE="STUDY">Bento 1991</LINK>). We included <LINK REF="STD-Austin-1993" TYPE="STUDY">Austin 1993</LINK>, previously excluded because of potential attrition bias, as current practice is to include all trials eligible according to the selection criteria.</P>
<P>Authors of the last version of this review included groups receiving antiviral therapy and considered the different comparisons from <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK> and <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK> as separate studies (Engström 2008b and Sullivan 2007b). We did not consider the two antiviral-treated participant groups from those trials in this updated review. These comparisons are included in the companion Cochrane review, 'Antiviral treatment for Bell's palsy (idiopathic facial paralysis)' (<LINK REF="REF-Gagyor-2015" TYPE="REFERENCE">Gagyor 2015</LINK>). In this update, we included only the comparisons of corticosteroid versus placebo or corticosteroids versus no treatment.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-07-12 17:04:46 +0100" MODIFIED_BY="[Empty name]">
<P>Summary details of the included trials are given in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>
<LINK REF="STD-Austin-1993" TYPE="STUDY">Austin 1993</LINK> recruited 107 participants whose symptoms had occurred within five days of presentation to the study centre. Of these, 31 participants did not return for initial follow-up. The 76 remaining participants subsequently entered a double-blinded randomised controlled study allocating them to a corticosteroid treatment group (prednisone) or a placebo group. The trial authors gave no details about binding or randomisation. Assessment of participants occurred within five days of onset and at "regular intervals until they experienced recovery from their acute paralysis". Final follow-up was at six months after recovery. The trial authors stated, "to be included in the analysis, patients must have completed follow up until their acute recovery occurred." Investigators measured disease status using the House-Brackmann grading system. At first evaluation, participants underwent various tests including blood tests, an audiogram, a nerve excitability test using the maximal stimulation technique and, if indicated, electroneurography. Treatment with prednisone was started at 30 mg twice daily for the first five days followed by a reducing dose stated by the trial authors.</P>
<P>The study reported final outcomes on 53 participants at six months after recovery. The primary outcome was time to recovery, for which trial authors found no statistically significant difference between the two groups. Secondary outcomes included facial paralysis grade at onset versus grade at recovery. There was a statistically significant difference in incomplete recovery rates favouring the treatment group: 5/23 participants receiving prednisone had incomplete recovery at six months versus 10/30 participants receiving placebo (RR 0.65, 95% CI 0.26 to 1.65). Investigators found no significant difference in persistence of pain during recovery, with 3/23 participants in the prednisone group still experiencing pain at six months, compared with 4/30 participants in the placebo group (RR 0.98, 95% CI 0.24 to 3.95).</P>
<P>
<A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Engstr_x00f6_m-2008">Engström 2008</A> had a factorial design that randomised 829 participants into four treatment groups using a two-stage computerised process. The four treatment groups were prednisolone with placebo, prednisolone with valaciclovir, valaciclovir with placebo, and double placebo. Treatment started within 72 hours of symptom onset. The trial was double-blind (administrator and participant) for assessment of recovery status until the end of follow-up. Participants were assessed at onset, after two weeks (11 to 17 days) and after 1, 2, 3, 6 and 12 months. Trialists measured disease status using the House-Brackmann grading system and the Sunnybrook scale, defining complete recovery status as a Sunnybrook score of 100 and a House-Brackmann grade of I. Data analysis included an assessment of treatment interaction.</P>
<P>The study reported a positive effect on recovery time due to prednisolone (comparing recovery rates at 12 months in the prednisolone group with the placebo group). For this review, we analysed the corticosteroid-placebo combination (OS) versus the double placebo combination (OO) 12 months after the onset of facial palsy. Using the Sunnybrook definition, 50/210 participants had an incomplete recovery with prednisolone compared with a greater proportion (73/206) in the placebo group (RR 0.67, 95% CI 0.50 to 0.91).</P>
<P>
<LINK REF="STD-Lagalla-2002" TYPE="STUDY">Lagalla 2002</LINK> randomised 62 participants within three days of onset of Bell's palsy to high-dose prednisone, 1 g daily for three days, then 0.5 g daily for three days, administered intravenously, using saline solution as a placebo. The age range was 15 to 84 years. Exclusion criteria included peptic ulcer disease, pregnancy, severe hypertension, other neurological conditions, diseases of the ear and previous treatment. As in <LINK REF="STD-Taverner-1954" TYPE="STUDY">Taverner 1954</LINK>, investigators excluded participants with herpes zoster oticus from the analyses (four of the participants initially randomised in <LINK REF="STD-Lagalla-2002" TYPE="STUDY">Lagalla 2002</LINK>). The investigators monitored participants for 12 months. They assessed recovery of facial motor function using the House-Brackmann scale. The trial authors reported the development of disabling synkinesis at 12-month follow-up.</P>
<P>
<LINK REF="STD-Lagalla-2002" TYPE="STUDY">Lagalla 2002</LINK> reported final outcomes on 58 participants at 12 months. In the prednisolone group, 5/30 participants had incomplete recovery, compared with 8/28 participants in the placebo group (RR 0.58, 95% CI 0.22 to 1.57).</P>
<P>
<LINK REF="STD-May-1976" TYPE="STUDY">May 1976</LINK> included 51 participants within two days of Bell's palsy onset and reported outcomes using clinical assessment and photographic documentation without a validated scoring system. The trial report did not specify the age range of participants in this double-blinded study. In the intervention group, participants received prednisone 410 mg in descending doses over 10 days. The placebo intervention was vitamins. Trialists excluded people with chronic otitis media, trauma, loss of lacrimation, or recurrent or bilateral palsy.</P>
<P>
<LINK REF="STD-May-1976" TYPE="STUDY">May 1976</LINK> was the only study that stated that there was no benefit from corticosteroids for the recovery of Bell's palsy (RR 1.16, 95% CI 0.57 to 2.36).</P>
<P>
<A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Sullivan-2007">Sullivan 2007</A> recruited 551 participants to be treated within 72 hours of onset. Participants were randomised by a dedicated remote telephone-computerised mechanism in a two-stage process into four treatment groups in a factorial design: prednisolone with placebo, prednisolone with aciclovir, aciclovir with placebo or double placebo. Participants received prednisolone 25 mg twice daily for 10 days. The trial was blinded for administrator, participant and assessment of recovery status until the end of follow-up. Assessments took place at onset, after three months and, if participants were still unwell, again after nine months. The investigators measured recovery status on the House-Brackmann scale, with complete recovery defined as House-Brackmann grade I. Data analysis included an assessment of treatment interaction.</P>
<P>
<A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Sullivan-2007">Sullivan 2007</A> reported final outcomes on 496 completed participants at three and nine months. In the corticosteroid (OS) group, 5/127 participants had incomplete recovery, compared with 18/122 participants in the placebo (OO) group (RR 0.27, 95% CI 0.10 to 0.70).</P>
<P>
<LINK REF="STD-Taverner-1954" TYPE="STUDY">Taverner 1954</LINK> was a double-blind trial that included 26 participants with a range of ages from 12 to 76 years within 10 days of onset of Bell's palsy. Participants received either oral cortisone acetate 1 g in descending doses over eight days or placebo tablets. Participants were monitored for up to 157 days. The trial excluded participants with other neurological conditions or diseases of the ear. <LINK REF="STD-Taverner-1954" TYPE="STUDY">Taverner 1954</LINK> included participants with herpes zoster oticus. These participants were allocated in equal numbers to each treatment arm, and trial authors excluded them from the analyses. The trialists did not used a validated scoring system to measure outcomes.</P>
<P>
<LINK REF="STD-Taverner-1954" TYPE="STUDY">Taverner 1954</LINK> used the recovery of facial motor function as the main outcome measure and reported a small, non-significant benefit of corticosteroids compared with placebo; CIs allowed for effects in either direction (RR 0.86, 95% CI 0.27 to 2.71).</P>
<P>
<LINK REF="STD-Unuvar-1999" TYPE="STUDY">Unuvar 1999</LINK> conducted a non-blinded, randomised controlled trial on children with severe to complete presentation of Bell's palsy (House-Brackmann grades IV to V). They randomised 42 children with an age range of 24 to 74 months using a computer-generated random sequence into two groups. All participants entered the trial within three days of onset of Bell's palsy and received either methylprednisolone 1 mg/kg daily for 10 days then gradually withdrawn over three to five days or no specific treatment. They excluded participants with other neurological conditions, diseases of the ear or systemic diseases. The primary outcome was the recovery of facial motor function measured on the House-Brackmann facial grading system.</P>
<P>
<LINK REF="STD-Unuvar-1999" TYPE="STUDY">Unuvar 1999</LINK> reported a benefit from the treatment with corticosteroids although wide CIs allowed for the possibility of both no effect and a large effect (RR 0.14, 95% CI 0.01 to 2.61).</P>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing studies</HEADING>
<P>We identified one trial report on the World Health Organization International Clinical Trials Registry Platform search portal (<LINK REF="STD-Babl-2015" TYPE="STUDY">Babl 2015</LINK>). From the website, it appeared that the study has now started recruitment; we will assess this trial fully in future review updates. See <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-07-12 12:41:11 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Akpinar-1979" TYPE="STUDY">Akpinar 1979</LINK> compared three groups of 10 participants each; two groups received different dosage regimens of corticosteroids, and the other received placebo. It was unclear who diagnosed the participants with Bell's palsy and there were varying dosage regimens of corticosteroids used. Two studies were not randomised or quasi-randomised (<LINK REF="STD-Brown-1982" TYPE="STUDY">Brown 1982</LINK>; <LINK REF="STD-Martinez-1990" TYPE="STUDY">Martinez 1990</LINK>). It was not possible to extract complete information on the specified outcomes for one study (<LINK REF="STD-Wolf-1978" TYPE="STUDY">Wolf 1978</LINK>). Finally, we excluded <LINK REF="STD-Bento-1991" TYPE="STUDY">Bento 1991</LINK> as number of participants and outcome events by treatment groups was not provided; in addition, 50% of the participants were lost to follow-up.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-07-12 17:04:55 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> summarises the 'Risk of bias' assessment for each included study.</P>
<ALLOCATION MODIFIED="2016-07-12 12:41:06 +0100" MODIFIED_BY="[Empty name]">
<P>All included trials reported the method of randomisation. Four used randomisation centralised at a pharmacy, in accordance with a master sheet of random numbers (<LINK REF="STD-May-1976" TYPE="STUDY">May 1976</LINK>; <LINK REF="STD-Taverner-1954" TYPE="STUDY">Taverner 1954</LINK>), or an automated permuted block technique (<LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>; <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>). One study used a random number list (<LINK REF="STD-Lagalla-2002" TYPE="STUDY">Lagalla 2002</LINK>), and another used a computer-based program (<LINK REF="STD-Unuvar-1999" TYPE="STUDY">Unuvar 1999</LINK>). It was not clear from the reports if there was adequate allocation concealment in <LINK REF="STD-Lagalla-2002" TYPE="STUDY">Lagalla 2002</LINK> or <LINK REF="STD-Unuvar-1999" TYPE="STUDY">Unuvar 1999</LINK>. We considered none of the trials to be at high risk of bias for random sequence generation or allocation concealment.</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-07-12 17:04:49 +0100" MODIFIED_BY="[Empty name]">
<P>Five trials were double-blind, using placebo in the control group (<LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>; <LINK REF="STD-Lagalla-2002" TYPE="STUDY">Lagalla 2002</LINK>; <LINK REF="STD-May-1976" TYPE="STUDY">May 1976</LINK>; <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>; <LINK REF="STD-Taverner-1954" TYPE="STUDY">Taverner 1954</LINK>). Two of these trials used lactose as the placebo (<LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>; <LINK REF="STD-Taverner-1954" TYPE="STUDY">Taverner 1954</LINK>), one used vitamins (<LINK REF="STD-May-1976" TYPE="STUDY">May 1976</LINK>), and one used a saline solution (<LINK REF="STD-Lagalla-2002" TYPE="STUDY">Lagalla 2002</LINK>). Two trials did not specify what was used as placebo, but they stated that this was formulated to have the same size, smell and colour (<LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>; <LINK REF="STD-Unuvar-1999" TYPE="STUDY">Unuvar 1999</LINK>). In the trial using vitamins as placebo, the experimental group received similar looking capsules containing prednisone plus vitamins. The trial using saline solution as placebo gave intramuscular vitamins to all participants for 15 days (<LINK REF="STD-Lagalla-2002" TYPE="STUDY">Lagalla 2002</LINK>). In one trial, it was not clear from the report if the physicians administering the drug were blinded (<LINK REF="STD-Lagalla-2002" TYPE="STUDY">Lagalla 2002</LINK>). There were no serious imbalances in baseline prognostic factors between groups.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-07-12 17:04:55 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>, <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>; and <LINK REF="STD-Taverner-1954" TYPE="STUDY">Taverner 1954</LINK> had drop-out rates of less than 10%. No participants dropped out in <LINK REF="STD-May-1976" TYPE="STUDY">May 1976</LINK>. <LINK REF="STD-Lagalla-2002" TYPE="STUDY">Lagalla 2002</LINK> included drop-outs in analyses on an intention-to-treat basis, by assuming that drop-outs had a poor outcome. <LINK REF="STD-Austin-1993" TYPE="STUDY">Austin 1993</LINK> had a drop-out rate of 50% for outcomes six months after recovery. <LINK REF="STD-Unuvar-1999" TYPE="STUDY">Unuvar 1999</LINK> did not report on attrition.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-06-22 15:11:17 +0100" MODIFIED_BY="Ruth  Brassington">
<P>All studies reported their intended primary outcomes. <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK> reported all primary outcomes, with secondary outcomes reported in subsequent publications (Axelsson 2012; Berg 2012).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-07-12 12:23:03 +0100" MODIFIED_BY="[Empty name]">
<P>We identified no other potential sources of bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-07-12 17:05:01 +0100" MODIFIED_BY="[Empty name]">
<P>As all trials reported different intervals and lengths of follow-up, we performed analyses on data reported at the end of the study periods. These were 157 days (<LINK REF="STD-Taverner-1954" TYPE="STUDY">Taverner 1954</LINK>), six months (<LINK REF="STD-May-1976" TYPE="STUDY">May 1976</LINK>; <LINK REF="STD-Austin-1993" TYPE="STUDY">Austin 1993</LINK>), nine months (<LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>), and 12 months (<LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>; <LINK REF="STD-Lagalla-2002" TYPE="STUDY">Lagalla 2002</LINK>; <LINK REF="STD-Unuvar-1999" TYPE="STUDY">Unuvar 1999</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete recovery of facial motor function six months or more after randomisation</HEADING>
<P>All seven trials, with 895 participants, provided data for the outcome complete recovery of facial motor function at six months' follow-up or more (we included data from <LINK REF="STD-Taverner-1954" TYPE="STUDY">Taverner 1954</LINK>, which reported at five months). The number of people with incomplete recovery at six months' follow-up was lower in the corticosteroid group compared to the control group (RR 0.63, 95% CI 0.50 to 0.80) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<P>The tests for statistical heterogeneity were marginally significant (Chi<SUP>2</SUP> = 7.32, P value = 0.29, I<SUP>2</SUP> = 18%). This small degree of heterogeneity was due to the differences in the findings between the large studies (<LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>; <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>), and small, underpowered studies (<LINK REF="STD-Austin-1993" TYPE="STUDY">Austin 1993</LINK>; <LINK REF="STD-Lagalla-2002" TYPE="STUDY">Lagalla 2002</LINK>; <LINK REF="STD-May-1976" TYPE="STUDY">May 1976</LINK>; <LINK REF="STD-Taverner-1954" TYPE="STUDY">Taverner 1954</LINK>; <LINK REF="STD-Unuvar-1999" TYPE="STUDY">Unuvar 1999</LINK>). There were better outcomes in two of the studies (<LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>; <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>).</P>
<P>The number of people who need to be treated with steroids to avoid one person with incomplete recovery was 10 (95% CI 6 to 20).</P>
<SUBSECTION>
<HEADING LEVEL="5">Sensitivity analyses</HEADING>
<P>We removed smaller underpowered studies (<LINK REF="STD-Austin-1993" TYPE="STUDY">Austin 1993</LINK>; <LINK REF="STD-Lagalla-2002" TYPE="STUDY">Lagalla 2002</LINK>; <LINK REF="STD-May-1976" TYPE="STUDY">May 1976</LINK>; <LINK REF="STD-Taverner-1954" TYPE="STUDY">Taverner 1954</LINK>; <LINK REF="STD-Unuvar-1999" TYPE="STUDY">Unuvar 1999</LINK>) from the main analysis leaving the two largest studies (<LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>; <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>). This analysis confirmed the size and direction of effect, but with higher statistical heterogeneity (RR 0.59, 95% CI 0.44 to 0.79, Chi<SUP>2 </SUP>= 3.32, I<SUP>2 </SUP>= 70%).</P>
<P>We analysed the main outcome for the studies that had the longest follow-up (i.e. between nine and 12 months) (<LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>; <LINK REF="STD-Lagalla-2002" TYPE="STUDY">Lagalla 2002</LINK>; <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>). This did not significantly change the result.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Cosmetically disabling persistent sequelae six months or more after randomisation</HEADING>
<P>Two trials with 75 participants provided data on the number of participants with severe paralysis, or what may be judged as cosmetically disabling sequelae, at six months' follow-up or more (<LINK REF="STD-May-1976" TYPE="STUDY">May 1976</LINK>; <LINK REF="STD-Taverner-1954" TYPE="STUDY">Taverner 1954</LINK>). When we combined the data, the number of participants with cosmetically disabling sequelae was similar in the corticosteroid group and the control group (RR 0.96, 95% CI 0.40 to 2.29) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Motor synkinesis or crocodile tears during follow-up</HEADING>
<P>Three trials, with 485 evaluable participants, reported separate data on motor synkinesis or crocodile tears during follow-up (<LINK REF="STD-Austin-1993" TYPE="STUDY">Austin 1993</LINK>; <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>; <LINK REF="STD-Lagalla-2002" TYPE="STUDY">Lagalla 2002</LINK>). Two trials reported the occurrence of disabling synkinesis at 12 months' follow-up (<LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>; <LINK REF="STD-Lagalla-2002" TYPE="STUDY">Lagalla 2002</LINK>); the other trial reported at six months' follow-up (<LINK REF="STD-Austin-1993" TYPE="STUDY">Austin 1993</LINK>). After pooling these data, we found a significant reduction in the number of people with motor synkinesis in the corticosteroid group (40/241) compared to the placebo group (64/248) (RR 0.64, 95% CI 0.45 to 0.91) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). We found no statistical heterogeneity (Chi<SUP>2</SUP> = 0.42, df = 2 (P = 0.81), I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects attributable to the use of corticosteroids</HEADING>
<P>Three studies explicitly recorded the absence of adverse effects attributable to the experimental treatment (<LINK REF="STD-May-1976" TYPE="STUDY">May 1976</LINK>; <LINK REF="STD-Taverner-1954" TYPE="STUDY">Taverner 1954</LINK>; <LINK REF="STD-Unuvar-1999" TYPE="STUDY">Unuvar 1999</LINK>). One trial reported that three participants receiving prednisone had temporary sleep disturbances (<LINK REF="STD-Lagalla-2002" TYPE="STUDY">Lagalla 2002</LINK>). Another reported "no severe side effects of steroid therapy", although there were single reported cases of mood swings, dyspepsia and minor conjunctivitis by individual participants (<LINK REF="STD-Austin-1993" TYPE="STUDY">Austin 1993</LINK>). Two trials gave a detailed account of 93 adverse effects (<LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>; <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>), all of them non-serious, with no significant difference between people receiving corticosteroids and people receiving placebo (RR 1.04, 95% CI 0.71 to 1.51). Three deaths occurred; all were deemed to be unrelated to treatment, all were in the groups not receiving prednisolone. One man with a history of recurrent atrial fibrillation had a transient relapse while taking prednisolone and valaciclovir (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analyses</HEADING>
<P>In this updated version of the review, we did not perform any subgroup analyses.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-07-12 17:43:14 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2016-07-12 17:43:14 +0100" MODIFIED_BY="[Empty name]">
<P>High-quality evidence from randomised controlled trials indicated benefit from the use of corticosteroids in Bell's palsy.</P>
<P>Two trials reached a statistically significant difference favouring the use of prednisolone (<LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>; <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>). Meta-analysis of the complete high-quality randomised controlled trial literature convincingly supported a beneficial effect of prednisolone for reducing the numbers of participants with incomplete recovery.</P>
<P>Moderate-quality evidence indicated that participants who received corticosteroid treatment had less motor synkinesis and crocodile tears than the placebo group.</P>
<P>Based on these two studies, low-quality evidence revealed no important differences between corticosteroids and placebo in cosmetically disabling persistent sequelae, but wide CIs allowed for the possibility of an effect in either direction.</P>
<P>The included studies did not report differences in the occurrence of adverse effects between corticosteroids and placebo and additionally no serious adverse effects were reported. However, corticosteroids have well-known adverse effects, of which the incidence rises markedly with prolonged dosages above 10 mg of prednisolone or its equivalent per day (<LINK REF="REF-Dollery-1999" TYPE="REFERENCE">Dollery 1999</LINK>). Usually corticosteroid courses in Bell's palsy are short and the dose quickly reduces, making the likelihood of adverse effects in practical use less than in longer-term indications.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-07-12 17:06:08 +0100" MODIFIED_BY="[Empty name]">
<P>No new studies have been published since the previous Cochrane review (<LINK REF="REF-Salinas-2010" TYPE="REFERENCE">Salinas 2010</LINK>). The two most recent, well-powered studies (<LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>; <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>), with five smaller studies (<LINK REF="STD-Austin-1993" TYPE="STUDY">Austin 1993</LINK>; <LINK REF="STD-Lagalla-2002" TYPE="STUDY">Lagalla 2002</LINK>; <LINK REF="STD-May-1976" TYPE="STUDY">May 1976</LINK>; <LINK REF="STD-Taverner-1954" TYPE="STUDY">Taverner 1954</LINK>; <LINK REF="STD-Unuvar-1999" TYPE="STUDY">Unuvar 1999</LINK>), provided a significant result based on the evidence provided. These studies sufficiently address the objectives of this review in that they investigate all relevant participants, interventions and outcomes. The findings are in accordance with suggested current clinical practice (<LINK REF="REF-Madhok-2009" TYPE="REFERENCE">Madhok 2009</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-07-12 17:43:14 +0100" MODIFIED_BY="[Empty name]">
<P>For the main outcome of this review (incomplete recovery six months or more after randomisation), all seven studies combined provided high-quality evidence. In addition, for motor synkinesis and crocodile tears, data from three studies provided moderate-quality evidence. Cosmetically disabling persistent sequelae six months or more after randomisation was the only analysis performed where the quality of evidence was low. For adverse effects, the evidence was moderate quality. Reasons for downgrading the quality of evidence were that in one study participants and assessors were not blinded to the treatment that they received (<LINK REF="STD-Unuvar-1999" TYPE="STUDY">Unuvar 1999</LINK>), and in another study, loss to follow-up was 50%, representing incomplete outcome data (<LINK REF="STD-Austin-1993" TYPE="STUDY">Austin 1993</LINK>). Two studies excluded participants who were found after randomisation to have clinical evidence of herpes zoster infection (<LINK REF="STD-Lagalla-2002" TYPE="STUDY">Lagalla 2002</LINK>; <LINK REF="STD-Taverner-1954" TYPE="STUDY">Taverner 1954</LINK>). Two studies did not use a standardised scale for assessment of facial motor function (<LINK REF="STD-May-1976" TYPE="STUDY">May 1976</LINK>; <LINK REF="STD-Taverner-1954" TYPE="STUDY">Taverner 1954</LINK>). We considered the effects of these factors on the quality of the evidence insufficient for further downgrading for indirectness of evidence. The results of the majority of studies in this review were consistent with each other, apart from those of one older, smaller study (<LINK REF="STD-May-1976" TYPE="STUDY">May 1976</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-07-12 12:25:51 +0100" MODIFIED_BY="[Empty name]">
<P>To help ensure that decisions about which studies to include in this review were reproducible, two review authors repeated the process (we divided the studies into three groups). There was no distinction made on the experience and expertise of each author in the reviewing pairs. On applying the eligibility criteria and assessing the relevance of studies, review authors were aware of the names of the study authors, institutions, journal of publication and results. FS and FD did not assess their own trial (<LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>). There were no final disagreements about which studies should be included. According to previous practice in this review, we excluded several studies and a published abstract that provided insufficient information. Therefore, there might be some risk of publication and selective reporting bias due to data from some studies being unavailable.<BR/>
</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-07-12 17:43:14 +0100" MODIFIED_BY="[Empty name]">
<P>Our results are coincident with three previous systematic reviews, which found that corticosteroids significantly improved the prognosis of people with Bell's palsy (<LINK REF="REF-de-Almeida-2009" TYPE="REFERENCE">de Almeida 2009</LINK>; <LINK REF="REF-Ramsey-2000" TYPE="REFERENCE">Ramsey 2000</LINK>; <LINK REF="REF-Williamson-1996" TYPE="REFERENCE">Williamson 1996</LINK>). All three reviews, even though of good quality, included a study that lost 50% of participants to follow-up (<LINK REF="STD-Bento-1991" TYPE="STUDY">Bento 1991</LINK>). Only one of them, <LINK REF="REF-de-Almeida-2009" TYPE="REFERENCE">de Almeida 2009</LINK>, was carried out after the publication of the largest trials included in our review (<LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>; <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>). Two of them (<LINK REF="REF-de-Almeida-2009" TYPE="REFERENCE">de Almeida 2009</LINK>; <LINK REF="REF-Ramsey-2000" TYPE="REFERENCE">Ramsey 2000</LINK>) also included a non-randomised study in the analyses (<LINK REF="STD-Martinez-1990" TYPE="STUDY">Martinez 1990</LINK>; <LINK REF="REF-Shafshak-1994" TYPE="REFERENCE">Shafshak 1994</LINK>). A Practice Parameter published by the American Academy of Neurology concluded that corticosteroids were safe and probably effective in improving facial functional outcomes in people with Bell's palsy (<LINK REF="REF-Grogan-2001" TYPE="REFERENCE">Grogan 2001</LINK>). This Practice Parameter was published, also, before the publication of <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK> and <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-07-12 13:23:53 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-07-12 13:23:53 +0100" MODIFIED_BY="[Empty name]">
<P>According to high-quality evidence, 10 people with Bell's palsy need to be treated with corticosteroids to avoid one incomplete recovery. The available evidence from randomised controlled trials shows that corticosteroids significantly reduce the frequency of incomplete recovery from Bell's palsy.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-10-30 00:03:01 +0000" MODIFIED_BY="[Empty name]">
<P>Further research on Bell's palsy treatment should consider giving corticosteroids to those participants acting as controls.</P>
<P>There should be no further studies that do not include corticosteroids as a treatment for Bell's palsy. No participants should be given placebo or no treatment in any future studies. There is an adequate body of evidence to support the use of corticosteroids in the treatment of Bell's palsy.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-07-12 17:05:58 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank the authors of previous editions of this review and we are very grateful for their hard work and enthusiasm. Our thanks are also extended to Angela Gunn who provided the search results and to Cochrane Neuromuscular for their extensive technical assistance and support.</P>
<P>The review has some sections in common with the Cochrane review 'Antiviral treatment for Bell's palsy (idiopathic facial paralysis)' (<LINK REF="REF-Gagyor-2015" TYPE="REFERENCE">Gagyor 2015</LINK>), which has been completed in parallel with this review by the same authors.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-06-29 09:36:01 +0100" MODIFIED_BY="Ruth  Brassington">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-07-12 12:26:32 +0100" MODIFIED_BY="[Empty name]">
<P>All six review authors worked in pairs on study selection and data extraction.</P>
<P>IG and VM agreed data input into Review Manager 5.</P>
<P>IG performed risk of bias assessments; FS and FD reviewed them.</P>
<P>IG and VM drafted the revised review.</P>
<P>FD assisted with calculations.</P>
<P>VM and IG revised the review after editorial review.</P>
<P>All authors approved the final draft.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-07-12 17:05:15 +0100" MODIFIED_BY="[Empty name]">
<P>A new author team updated this review: Vishnu B Madhok, Ildiko Gagyor, Fergus Daly, Dhruvashree Somasundara, Michael Sullivan, Fiona Gammie, Frank Sullivan.</P>
<P>The review authors added a 'Summary of findings' table and added some sections to the Methods to comply with current Cochrane standards.</P>
<SUBSECTION>
<HEADING LEVEL="2">Changes from the previous update of this review</HEADING>
<P>When looking at <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK> and <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>, we excluded participants that were given antiviral therapy with corticosteroids or antiviral therapy alone as these are reported in a separate review (<LINK REF="REF-Gagyor-2015" TYPE="REFERENCE">Gagyor 2015</LINK>).</P>
<P>As a result, in this update we deleted the comparisons from those trials that the previous review authors designated Sullivan b and Engström b.</P>
<P>We assume that the total number of events given in Engström a (i.e. 213) was incorrect, and changed the figure to 210.</P>
<P>In the previous Cochrane review, authors used intention-to-treat numbers. We decided to perform available-case analysis unless the trialists reported intention-to-treat data.</P>
<P>We deleted Sullivan b from Table 1.2 "cosmetically disabling persistent sequelae" for the reasons above. Sullivan a did not contribute data to this table.</P>
<P>In <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>, "motor synkinesis of or autonomic dysfunction during follow up", we deleted Engström b for the reasons above.</P>
<P>In <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>, we changed the data for Engström a - the previous Cochrane review correctly gave the number of participants reporting synkinesis at 12 months in the OS group as 32. We continued to use this event rate, but changed the total sample number from 290 to 186 in accordance with the information given.</P>
<P>We deleted what was previously Analysis 1.4 "incomplete recovery of patients with Bell's Palsy" as the numbers of participants was negligible (only 22 participants from two studies Sullivan a and <LINK REF="STD-May-1976" TYPE="STUDY">May 1976</LINK>), after we removed the data from Sullivan b.</P>
<P>We checked the numbers for <LINK REF="STD-May-1976" TYPE="STUDY">May 1976</LINK>; <LINK REF="STD-Taverner-1954" TYPE="STUDY">Taverner 1954</LINK>; and <LINK REF="STD-Unuvar-1999" TYPE="STUDY">Unuvar 1999</LINK>. We found that the numbers included for Taverner were incorrect and updated these in <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.</P>
<P>The previous Cochrane review excluded <LINK REF="STD-Lagalla-2002" TYPE="STUDY">Lagalla 2002</LINK> from the main meta-analysis giving the reason that the paper did not provide primary outcome data on complete recovery. We decided to include this study given that we could use information on page 109 (results section) of the paper to calculate the data for input into <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>. In the prednisolone group, 32 participants, 83%, had complete recovery, hence 17% (five participants) had incomplete recovery. In the placebo group, there were 30 participants, of whom 25% (eight participants) had incomplete recovery.</P>
<P>Based on our changes to <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>, the RR changed from 0.51 (95% CI 0.32 to 0.80) to 0.65 (95% CI 0.50 to 0.83).</P>
<P>We added a table of adverse effects (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>We checked the data for each of the included studies and made significant amendments and corrections in the <LINK TAG="INTERVENTION_EFFECTS" TYPE="SECTION">Effects of interventions</LINK> section.</P>
<P>In the <LINK TAG="OBJECTIVES" TYPE="SECTION">Objectives</LINK>, we deleted the reference to 'early' use of corticosteroids in Bell's palsy.</P>
</SUBSECTION>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-07-12 17:44:55 +0100" MODIFIED_BY="Ruth Brassington">
<STUDIES MODIFIED="2016-07-12 17:05:41 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2016-07-12 17:05:41 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Austin-1993" MODIFIED="2016-07-11 20:30:32 +0100" MODIFIED_BY="Anne Lawson" NAME="Austin 1993" YEAR="1993">
<REFERENCE MODIFIED="2016-07-11 20:30:32 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Austin JR, Peskind SP, Austin SG, Rice DH</AU>
<TI>Idiopathic facial nerve paralysis: a randomized double blind controlled study of placebo versus prednisone</TI>
<SO>Laryngoscope</SO>
<YR>1993</YR>
<VL>103</VL>
<NO>12</NO>
<PG>1326-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2918850"/><IDENTIFIER TYPE="PUBMED" VALUE="8246650"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2918849"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Engstr_x00f6_m-2008" MODIFIED="2016-07-12 17:05:41 +0100" MODIFIED_BY="[Empty name]" NAME="Engström 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-07-12 17:05:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Axelsson S, Berg T, Jonsson L, Engström M, Kanerva M, Stjernquist-Desatnik A</AU>
<TI>Bell's palsy - the effect of prednisolone and/or valaciclovir versus placebo in relation to baseline severity in a randomised controlled trial</TI>
<SO>Clinical Otolaryngology</SO>
<YR>2012</YR>
<VL>37</VL>
<NO>4</NO>
<PG>283-90</PG>
<IDENTIFIERS MODIFIED="2016-03-04 15:38:54 +0000" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2918852"/><IDENTIFIER MODIFIED="2016-03-04 15:38:54 +0000" MODIFIED_BY="Angela A Gunn" TYPE="EMBASE" VALUE="2012510516"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-07-11 20:30:02 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berg T, Bylund N, Marsk E, Jonsson L, Kanerva M, Hultcrantz M, et al</AU>
<TI>The effect of prednisolone on sequelae in Bell's palsy</TI>
<SO>Archives of Otolaryngology - Head &amp; Neck Surgery</SO>
<YR>2012</YR>
<VL>138</VL>
<NO>5</NO>
<PG>445-9</PG>
<IDENTIFIERS MODIFIED="2016-03-04 15:41:20 +0000" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2918853"/><IDENTIFIER MODIFIED="2016-03-04 15:41:20 +0000" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="22652942"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-10-15 21:56:22 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Engström M, Berg T, Stjemquist-Desatnik A, Axelsson S, Pitkäranta A, Hultcrantz M, et al</AU>
<TI>Prednisolone and valaciclovir in Bell's palsy: a randomised double-blind, placebo controlled, multicentre trial</TI>
<SO>Lancet Neurology</SO>
<YR>2008</YR>
<VL>7</VL>
<NO>11</NO>
<PG>993-1000</PG>
<IDENTIFIERS MODIFIED="2015-10-15 21:56:22 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2918854"/><IDENTIFIER MODIFIED="2015-10-15 21:56:22 +0100" MODIFIED_BY="Ruth Brassington" TYPE="PUBMED" VALUE="18849193"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-02-22 19:47:12 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2918851"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lagalla-2002" MODIFIED="2016-07-11 20:30:39 +0100" MODIFIED_BY="Anne Lawson" NAME="Lagalla 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-07-11 20:30:39 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lagalla G, Logullo F, Di Bella P, Provinciali F, Ceravolo MG</AU>
<TI>Influence of early high-dose steroid treatment on Bell's palsy evolution</TI>
<SO>Neurological Sciences</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>3</NO>
<PG>107-12</PG>
<IDENTIFIERS MODIFIED="2011-11-14 13:47:50 +0000" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2918856"/><IDENTIFIER MODIFIED="2011-11-14 13:47:50 +0000" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="12391494"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2918855"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-May-1976" MODIFIED="2016-07-11 20:30:51 +0100" MODIFIED_BY="Anne Lawson" NAME="May 1976" YEAR="1976">
<REFERENCE MODIFIED="2016-07-11 20:30:51 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>May M, Wette R, Hardin WB Jr, Sullivan J</AU>
<TI>The use of steroids in Bell's palsy: a prospective controlled study</TI>
<SO>Laryngoscope</SO>
<YR>1976</YR>
<VL>86</VL>
<NO>8</NO>
<PG>1111-22</PG>
<IDENTIFIERS MODIFIED="2011-11-14 13:48:43 +0000" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2918858"/><IDENTIFIER MODIFIED="2011-11-14 13:48:43 +0000" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="781439"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2918857"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sullivan-2007" MODIFIED="2016-07-11 20:31:04 +0100" MODIFIED_BY="Anne Lawson" NAME="Sullivan 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-07-11 20:31:04 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sullivan FM, Swan IRC, Donnan PT, Morrison JM, Smith BH, McKinstry B, et al</AU>
<TI>Early treatment with prednisolone or acyclovir in Bell´s Palsy</TI>
<SO>New England Journal of Medicine</SO>
<YR>2007</YR>
<VL>357</VL>
<NO>16</NO>
<PG>1598-607</PG>
<IDENTIFIERS MODIFIED="2012-11-05 16:26:57 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2918860"/><IDENTIFIER MODIFIED="2012-11-05 16:26:57 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17942873"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2918859"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taverner-1954" MODIFIED="2016-07-11 20:31:18 +0100" MODIFIED_BY="Anne Lawson" NAME="Taverner 1954" YEAR="1954">
<REFERENCE MODIFIED="2016-07-11 20:31:18 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taverner D</AU>
<TI>Cortisone treatment of Bell's palsy</TI>
<SO>Lancet</SO>
<YR>1954</YR>
<VL>264</VL>
<NO>6847</NO>
<PG>1052-4</PG>
<IDENTIFIERS MODIFIED="2012-11-05 16:44:11 +0000" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2918862"/><IDENTIFIER MODIFIED="2012-11-05 16:44:11 +0000" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="13213115"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2918861"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Unuvar-1999" MODIFIED="2016-07-11 20:31:26 +0100" MODIFIED_BY="Anne Lawson" NAME="Unuvar 1999" YEAR="1999">
<REFERENCE MODIFIED="2016-07-11 20:31:26 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Unuvar E, Oguz F, Sidal M, Kilic A</AU>
<TI>Corticosteroid treatment of childhood Bell's palsy</TI>
<SO>Pediatric Neurology</SO>
<YR>1999</YR>
<VL>21</VL>
<NO>5</NO>
<PG>814-6</PG>
<IDENTIFIERS MODIFIED="2011-11-14 13:51:10 +0000" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2918864"/><IDENTIFIER MODIFIED="2011-11-14 13:51:10 +0000" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="10593672"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2918863"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-07-11 20:32:09 +0100" MODIFIED_BY="Anne Lawson">
<STUDY DATA_SOURCE="PUB" ID="STD-Akpinar-1979" MODIFIED="2016-06-22 11:32:11 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Akpinar 1979" YEAR="1979">
<REFERENCE MODIFIED="2016-06-22 11:32:11 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akpinar S, Boga M, Yardim M</AU>
<TI>Steroid versus placebo treatments in cases of acute peripheral facial paralysis</TI>
<TO>Akut periferik fasiyel paralizi olgularinda steroid tedavisinin plasebo ile oranlanmasi</TO>
<SO>Bulletin of Gulhane Military Medical Academy</SO>
<YR>1979</YR>
<VL>21</VL>
<PG>45-51</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2918866"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2918865"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bento-1991" MODIFIED="2016-01-26 11:59:05 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Bento 1991" YEAR="1991">
<REFERENCE MODIFIED="2016-01-26 11:59:05 +0000" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bento RF, Bogar P, Lorenzi MC</AU>
<TI>Treatment comparison between dexamethasone and placebo for idiopathic facial palsy</TI>
<SO>European Archives of Oto-Rhino-Laryngology</SO>
<YR>1994</YR>
<VL>suppl</VL>
<PG>S535-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2918868"/><IDENTIFIER TYPE="PUBMED" VALUE="10774443"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-15 17:22:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bento RF, Lorenzi MC, Bogar P, Marone SA, Minili A</AU>
<TI>Comparison between dexametasone and placebo for idiopathic facial palsy</TI>
<TO>Comparacao entre a dexametasona e placebo no tratamento da paralisia facial periferica idiopatica</TO>
<SO>Revista Brasileira de Otorrinolaringologia</SO>
<YR>1991</YR>
<VL>57</VL>
<PG>196-202</PG>
<IDENTIFIERS MODIFIED="2011-11-15 17:22:06 +0000" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2918869"/><IDENTIFIER MODIFIED="2011-11-15 17:22:06 +0000" MODIFIED_BY="Angela A Gunn" TYPE="EMBASE" VALUE="92038773"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2918867"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-1982" MODIFIED="2016-07-11 20:31:56 +0100" MODIFIED_BY="Anne Lawson" NAME="Brown 1982" YEAR="1982">
<REFERENCE MODIFIED="2016-07-11 20:31:56 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown JS</AU>
<TI>Bell's palsy: a 5 year review of 174 consecutive cases: an attempted double blind study</TI>
<SO>Laryngoscope</SO>
<YR>1982</YR>
<VL>92</VL>
<NO>12</NO>
<PG>1369-73</PG>
<IDENTIFIERS MODIFIED="2011-11-14 14:03:04 +0000" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2918871"/><IDENTIFIER MODIFIED="2011-11-14 14:03:04 +0000" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="6757616"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2918870"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martinez-1990" NAME="Martinez 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martinez CG, Abarca B, Alvardo CL</AU>
<TI>Bell's palsy: evaluation of steroid treatment</TI>
<TO>Paralisis de Bell: Evaluacion del tratamiento esteroidal</TO>
<SO>Boletin del hospital de San Juan de Dios</SO>
<YR>1990</YR>
<VL>37</VL>
<NO>1</NO>
<PG>13-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2918873"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2918872"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolf-1978" MODIFIED="2016-07-11 20:32:09 +0100" MODIFIED_BY="Anne Lawson" NAME="Wolf 1978" YEAR="1978">
<REFERENCE MODIFIED="2016-07-11 20:32:09 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolf SM, Wagner JH, Davidson S, Forsythe A</AU>
<TI>Treatment of Bell palsy with prednisone: a prospective, randomized study</TI>
<SO>Neurology</SO>
<YR>1978</YR>
<VL>28</VL>
<NO>2</NO>
<PG>158-61</PG>
<IDENTIFIERS MODIFIED="2016-05-23 13:06:16 +0100" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2918875"/><IDENTIFIER MODIFIED="2011-11-14 14:05:35 +0000" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="340980"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2918874"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-09-14 15:56:59 +0100" MODIFIED_BY="Ruth Brassington"/>
<ONGOING_STUDIES MODIFIED="2015-07-14 23:26:19 +0100" MODIFIED_BY="Ruth  Brassington">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Babl-2015" MODIFIED="2015-07-14 23:26:05 +0100" MODIFIED_BY="[Empty name]" NAME="Babl 2015" YEAR="2015">
<IDENTIFIERS MODIFIED="2015-07-14 23:25:47 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-07-14 23:25:41 +0100" MODIFIED_BY="[Empty name]" OTHERTYPE="ACTRN" TYPE="OTHER" VALUE="12615000563561"/><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2918876"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-07-12 17:44:08 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2016-07-12 17:44:08 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Adour-1972" MODIFIED="2012-11-05 16:53:47 +0000" MODIFIED_BY="Angela A Gunn" NAME="Adour 1972" TYPE="JOURNAL_ARTICLE">
<AU>Adour KK, Wingerd J, Bell DN, Manning JJ, Hurley JP</AU>
<TI>Prednisone treatment for idiopathic facial paralysis (Bell's palsy)</TI>
<SO>New England Journal of Medicine</SO>
<YR>1972</YR>
<VL>287</VL>
<NO>25</NO>
<PG>1268-72</PG>
<IDENTIFIERS MODIFIED="2012-11-05 16:53:47 +0000" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-Adour-1982" MODIFIED="2016-03-29 09:09:05 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Adour 1982" TYPE="JOURNAL_ARTICLE">
<AU>Adour KK</AU>
<TI>Current concepts in neurology: diagnosis and management of facial paralysis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1982</YR>
<VL>307</VL>
<NO>6</NO>
<PG>348-51</PG>
<IDENTIFIERS MODIFIED="2012-11-05 16:53:56 +0000" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-Bateman-1992" MODIFIED="2016-07-12 12:35:56 +0100" MODIFIED_BY="[Empty name]" NAME="Bateman 1992" TYPE="JOURNAL_ARTICLE">
<AU>Bateman JE</AU>
<TI>Facial palsy</TI>
<SO>British Journal of Hospital Medicine</SO>
<YR>1992</YR>
<VL>47</VL>
<NO>6</NO>
<PG>430-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brandenberg-1993" MODIFIED="2016-03-29 09:11:00 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Brandenberg 1993" TYPE="JOURNAL_ARTICLE">
<AU>Brandenberg NA, Annegers JF</AU>
<TI>Incidence and risk factors for Bell's palsy in Laredo, Texas</TI>
<SO>Neuroepidemiology</SO>
<YR>1993</YR>
<VL>12</VL>
<NO>6</NO>
<PG>313-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burgess-1984" MODIFIED="2012-11-05 16:54:04 +0000" MODIFIED_BY="Angela A Gunn" NAME="Burgess 1984" TYPE="JOURNAL_ARTICLE">
<AU>Burgess LP, Yim DW, Lepore ML</AU>
<TI>Bell's palsy: the controversy revisited</TI>
<SO>Laryngoscope</SO>
<YR>1984</YR>
<VL>94</VL>
<NO>11 pt 1</NO>
<PG>1472-6</PG>
<IDENTIFIERS MODIFIED="2012-11-05 16:54:04 +0000" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-de-Almeida-2009" MODIFIED="2010-02-04 16:58:13 +0000" MODIFIED_BY="Ruth Brassington" NAME="de Almeida 2009" TYPE="JOURNAL_ARTICLE">
<AU>de Almeida JR, Al Khabori M, Guyatt GH, Witterick IJ, Lin VYW, Nedzelski JM, et al</AU>
<TI>Combined corticosteroid and antiviral treatment for Bell palsy: a systematic review and meta-analysis</TI>
<SO>JAMA</SO>
<YR>2009</YR>
<VL>302</VL>
<NO>9</NO>
<PG>985-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dollery-1999" MODIFIED="2011-11-14 14:12:56 +0000" MODIFIED_BY="Angela A Gunn" NAME="Dollery 1999" TYPE="BOOK">
<AU>Dollery C</AU>
<SO>Therapeutic Drugs</SO>
<YR>1999</YR>
<VL>2</VL>
<EN>2nd</EN>
<PB>Churchill Livingstone</PB>
<CY>Edinburgh</CY>
<IDENTIFIERS MODIFIED="2011-11-14 14:12:56 +0000" MODIFIED_BY="Angela A Gunn"><IDENTIFIER MODIFIED="2011-11-14 14:12:56 +0000" MODIFIED_BY="Angela A Gunn" TYPE="OTHER" VALUE="ISBN: 0443051488 (2 volumes)"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-2007" MODIFIED="2014-10-29 22:27:21 +0000" MODIFIED_BY="[Empty name]" NAME="Egger 2007" TYPE="BOOK">
<AU>Egger M, Davey Smith G, Altman DG</AU>
<SO>Systematic Reviews in Health Care: Meta-Analysis in context</SO>
<YR>2007</YR>
<EN>6th</EN>
<PB>BMJ Books</PB>
<CY>London</CY>
<IDENTIFIERS MODIFIED="2014-10-29 22:27:02 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Gagyor-2015" MODIFIED="2016-07-12 12:36:08 +0100" MODIFIED_BY="[Empty name]" NAME="Gagyor 2015" TYPE="COCHRANE_REVIEW">
<AU>Gagyor I, Madhok VB, Daly F, Somasundara D, Sullivan M, Gammie F, et al</AU>
<TI>Antiviral treatment for Bell's palsy (idiopathic facial paralysis)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2016-03-29 12:26:18 +0100" MODIFIED_BY="Ruth  Brassington"><IDENTIFIER MODIFIED="2016-03-29 12:26:18 +0100" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001869.pub8"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-2008" MODIFIED="2016-07-12 12:36:23 +0100" MODIFIED_BY="[Empty name]" NAME="GRADEpro 2008" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro</TI>
<YR>2008</YR>
<EN>3.2 for Windows</EN>
<PB>McMaster University</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grogan-2001" MODIFIED="2016-07-12 12:36:29 +0100" MODIFIED_BY="[Empty name]" NAME="Grogan 2001" TYPE="JOURNAL_ARTICLE">
<AU>Grogan PM, Gronseth GS</AU>
<TI>Practice parameter: steroids, acyclovir, and surgery for Bell's palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>56</VL>
<NO>7</NO>
<PG>830-6</PG>
<IDENTIFIERS MODIFIED="2012-11-05 16:54:15 +0000" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-07-12 12:36:42 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS MODIFIED="2016-03-29 12:24:13 +0100" MODIFIED_BY="Ruth  Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Katusic-1986" MODIFIED="2016-06-09 23:43:53 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Katusic 1986" TYPE="JOURNAL_ARTICLE">
<AU>Katusic SK, Beard CM, Wiederholt WC, Bergstrahl EJ, Kurland LT</AU>
<TI>Incidence, clinical features, and prognosis in Bell's palsy, Rochester, Minnesota</TI>
<SO>Annals of Neurology</SO>
<YR>1986</YR>
<VL>20</VL>
<NO>5</NO>
<PG>622-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lackner-2010" MODIFIED="2016-07-12 12:36:58 +0100" MODIFIED_BY="[Empty name]" NAME="Lackner 2010" TYPE="JOURNAL_ARTICLE">
<AU>Lackner A, Kessler HH, Walch C, Quasthoff S, Raggam RB</AU>
<TI>Early and reliable detection of herpes simplex virus type 1 and varicella zoster virus DNAs in oral fluid of patients with idiopathic peripheral facial nerve palsy: decision support regarding antiviral treatment?</TI>
<SO>Journal of Medical Virology</SO>
<YR>2010</YR>
<VL>82</VL>
<NO>9</NO>
<PG>1582-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Madhok-2009" MODIFIED="2016-07-12 12:37:15 +0100" MODIFIED_BY="[Empty name]" NAME="Madhok 2009" TYPE="JOURNAL_ARTICLE">
<AU>Madhok V, Falk G, Fahey T, Sullivan F</AU>
<TI>Prescribe prednisolone alone for Bell's palsy diagnosed within 72 hours of symptom onset</TI>
<SO>BMJ</SO>
<YR>2009</YR>
<VL>338</VL>
<PG>255</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martyn-1997" MODIFIED="2012-11-05 16:54:31 +0000" MODIFIED_BY="Angela A Gunn" NAME="Martyn 1997" TYPE="JOURNAL_ARTICLE">
<AU>Martyn CN, Hughes RA</AU>
<TI>Epidemiology of peripheral neuropathy</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>1997</YR>
<VL>62</VL>
<NO>4</NO>
<PG>310-8</PG>
<IDENTIFIERS MODIFIED="2012-11-05 16:54:31 +0000" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-Morales-2013" MODIFIED="2016-07-12 12:37:31 +0100" MODIFIED_BY="[Empty name]" NAME="Morales 2013" TYPE="JOURNAL_ARTICLE">
<AU>Morales DR, Donnan PT, Daly F, Van Staa T, Sullivan F</AU>
<TI>Impact of clinical trial findings on Bell's palsy management in general practice in the UK 2001-2012: interrupted time series regression analysis</TI>
<SO>BMJ Open</SO>
<YR>2013</YR>
<VL>3</VL>
<NO>7</NO>
<PG>e003121</PG>
<IDENTIFIERS MODIFIED="2016-03-29 09:13:48 +0100" MODIFIED_BY="Ruth  Brassington"><IDENTIFIER MODIFIED="2016-03-29 09:13:48 +0100" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1136/bmjopen-2013-003121"/><IDENTIFIER MODIFIED="2016-03-29 09:13:31 +0100" MODIFIED_BY="Ruth  Brassington" TYPE="PUBMED" VALUE="23864211"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Murakami-1996" MODIFIED="2012-11-05 16:54:44 +0000" MODIFIED_BY="Angela A Gunn" NAME="Murakami 1996" TYPE="JOURNAL_ARTICLE">
<AU>Murakami S, Mizobuchi M, Nakashiro Y, Doi T, Hato N, Yanagihara N</AU>
<TI>Bell palsy and herpes simplex virus: identification of viral DNA in endoneurial fluid and muscle</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1996</YR>
<VL>124</VL>
<NO>1 pt 1</NO>
<PG>27-30</PG>
<IDENTIFIERS MODIFIED="2012-11-05 16:54:44 +0000" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-Niparko-1993" MODIFIED="2016-07-12 12:37:41 +0100" MODIFIED_BY="[Empty name]" NAME="Niparko 1993" TYPE="BOOK_SECTION">
<AU>Niparko JK, Mattox DE</AU>
<TI>Bell's palsy and herpes zoster oticus</TI>
<SO>Current Therapy in Neurologic Disease</SO>
<YR>1993</YR>
<PG>355-61</PG>
<EN>4th</EN>
<ED>Johnson RT, Griffin JW</ED>
<PB>BC Decker</PB>
<CY>St. Louis, MO</CY>
<IDENTIFIERS><IDENTIFIER TYPE="OTHER" VALUE="ISBN: 0801677300"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Peitersen-1982" MODIFIED="2012-11-05 16:54:53 +0000" MODIFIED_BY="Angela A Gunn" NAME="Peitersen 1982" TYPE="JOURNAL_ARTICLE">
<AU>Peitersen E</AU>
<TI>The natural history of Bell's palsy</TI>
<SO>American Journal of Otology</SO>
<YR>1982</YR>
<VL>4</VL>
<NO>2</NO>
<PG>107-11</PG>
<IDENTIFIERS MODIFIED="2012-11-05 16:54:53 +0000" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-Peitersen-2002" MODIFIED="2016-07-12 12:37:22 +0100" MODIFIED_BY="[Empty name]" NAME="Peitersen 2002" TYPE="JOURNAL_ARTICLE">
<AU>Peitersen E</AU>
<TI>Bell's palsy: the spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies</TI>
<SO>Acta Otolaryngologica Supplementum</SO>
<YR>2002</YR>
<VL>549</VL>
<PG>4-30</PG>
<IDENTIFIERS MODIFIED="2015-08-05 15:49:30 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Prescott-1988" MODIFIED="2012-11-05 16:55:23 +0000" MODIFIED_BY="Angela A Gunn" NAME="Prescott 1988" TYPE="JOURNAL_ARTICLE">
<AU>Prescott CA</AU>
<TI>Idiopathic facial nerve palsy (the effect of treatment with steroids)</TI>
<SO>Journal of Laryngology &amp; Otology</SO>
<YR>1988</YR>
<VL>102</VL>
<NO>5</NO>
<PG>403-7</PG>
<IDENTIFIERS MODIFIED="2012-11-05 16:55:23 +0000" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-Ramsey-2000" MODIFIED="2012-11-05 16:55:06 +0000" MODIFIED_BY="Ruth Brassington" NAME="Ramsey 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ramsey MJ, DerSimonian R, Holtel MR, Burgess LP</AU>
<TI>Corticosteroid treatment for idiopathic facial nerve palsy: a meta analysis</TI>
<SO>Laryngoscope</SO>
<YR>2000</YR>
<VL>110</VL>
<NO>3 pt 1</NO>
<PG>335-41</PG>
<IDENTIFIERS MODIFIED="2012-11-05 16:55:06 +0000" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2016-06-09 23:44:13 +0100" MODIFIED_BY="Ruth  Brassington" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shafshak-1994" MODIFIED="2012-11-05 16:55:16 +0000" MODIFIED_BY="Angela A Gunn" NAME="Shafshak 1994" TYPE="JOURNAL_ARTICLE">
<AU>Shafshak TS, Essa AY, Bakey FA</AU>
<TI>The possible contributing factors for the success of steroid therapy in Bell's palsy: a clinical and electrophysiological study</TI>
<SO>Journal of Laryngology and Otology</SO>
<YR>1994</YR>
<VL>108</VL>
<NO>11</NO>
<PG>940-3</PG>
<IDENTIFIERS MODIFIED="2012-11-05 16:55:16 +0000" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-Victor-1994" MODIFIED="2016-06-09 23:41:54 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Victor 1994" TYPE="BOOK_SECTION">
<AU>Victor M, Martin J</AU>
<TI>Disorders of the cranial nerves</TI>
<SO>Harrison's Principles of Internal Medicine</SO>
<YR>1994</YR>
<PG>2347-52</PG>
<EN>13th</EN>
<ED>Isselbacher KJ, Wilson J, Fauci A, Braunwald E, Martin J, Kasper D</ED>
<PB>McGraw-Hill</PB>
<CY>New York</CY>
<IDENTIFIERS><IDENTIFIER TYPE="OTHER" VALUE="ISBN: 0070323704"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Williamson-1996" MODIFIED="2012-11-05 16:55:38 +0000" MODIFIED_BY="Angela A Gunn" NAME="Williamson 1996" TYPE="JOURNAL_ARTICLE">
<AU>Williamson IG, Whelan TR</AU>
<TI>The clinical problem of Bell's palsy: is treatment with steroids effective?</TI>
<SO>British Journal of General Practice</SO>
<YR>1996</YR>
<VL>46</VL>
<NO>413</NO>
<PG>743-7</PG>
<IDENTIFIERS MODIFIED="2012-11-05 16:55:38 +0000" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-Yanagihara-1988" MODIFIED="2016-03-29 09:22:38 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Yanagihara 1988" TYPE="JOURNAL_ARTICLE">
<AU>Yanagihara N, Yumoto E, Shibahara T</AU>
<TI>Familial Bell's palsy: analysis of 25 families</TI>
<SO>Annals of Otology, Rhinology and Laryngology</SO>
<YR>1988</YR>
<VL>137</VL>
<NO>Suppl</NO>
<PG>8-10</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-06-29 09:36:20 +0100" MODIFIED_BY="Ruth  Brassington">
<REFERENCE ID="REF-Salinas-2002" MODIFIED="2016-03-29 12:43:44 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Salinas 2002" TYPE="COCHRANE_REVIEW">
<AU>Salinas RA, Alvarez G, Alvarez MI, Ferreira J</AU>
<TI>Corticosteroids for Bell's palsy (idiopathic facial paralysis)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2016-03-29 12:43:44 +0100" MODIFIED_BY="Ruth  Brassington"><IDENTIFIER MODIFIED="2016-03-29 12:43:44 +0100" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001942"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Salinas-2004" MODIFIED="2016-06-29 09:36:20 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Salinas 2004" TYPE="COCHRANE_REVIEW">
<AU>Salinas RA, Alvarez G, Ferreira J</AU>
<TI>Corticosteroids for Bell's palsy (idiopathic facial paralysis)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2016-03-29 12:42:19 +0100" MODIFIED_BY="Ruth  Brassington"><IDENTIFIER MODIFIED="2016-03-29 12:42:19 +0100" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001942.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Salinas-2009" MODIFIED="2016-06-09 23:45:14 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Salinas 2009" TYPE="COCHRANE_REVIEW">
<AU>Salinas RA, Alvarez G, Ferreira J</AU>
<TI>Corticosteroids for Bell's palsy (idiopathic facial paralysis)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2016-03-29 12:42:36 +0100" MODIFIED_BY="Ruth  Brassington"><IDENTIFIER MODIFIED="2016-03-29 12:42:36 +0100" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001942.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Salinas-2010" MODIFIED="2016-03-29 12:41:44 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Salinas 2010" TYPE="COCHRANE_REVIEW">
<AU>Salinas RA, Alvarez G, Daly F, Ferreira J</AU>
<TI>Corticosteroids for Bell's palsy (idiopathic facial paralysis)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2016-03-29 12:41:44 +0100" MODIFIED_BY="Ruth  Brassington"><IDENTIFIER MODIFIED="2016-03-29 12:41:44 +0100" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001942.pub4"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-07-12 17:05:26 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-07-12 17:05:24 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Funding" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Conflicts of interest" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Date conducted">
<INCLUDED_CHAR MODIFIED="2016-07-12 17:05:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Austin-1993">
<CHAR_METHODS MODIFIED="2016-07-12 12:28:11 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, randomised, controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-12 17:05:15 +0100" MODIFIED_BY="[Empty name]">
<P>107 people were initially randomised; 76 completed follow-up until acute recovery and were included in the study analyses</P>
<P>Participants were treated within 5 days of onset</P>
<P>Sex: male 39 (51%), female 37 (49%)</P>
<P>Age: mean 36.8 years, range 18 to 70 years</P>
<P>37 cases (49%) right side palsy and 39 cases (51%) left side palsy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-12 12:28:45 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Prednisone (n = 35): in a scheduled dosage (30 mg twice daily for 5 days reducing to 20 mg twice daily on day 6, 15 mg twice daily on day 7, 10 mg twice daily on day 8, 5 mg twice daily on day 9, and 5 mg once daily on day 10)</LI>
</UL>
<UL>
<LI>Equivalent placebo (n = 31)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-12 12:29:39 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome:</P>
<UL>
<LI>time to resolution in days of facial function as defined by the House-Brackmann scale</LI>
</UL>
<P>Secondary outcomes:</P>
<UL>
<LI>distribution of facial nerve grade at 6 months after recovery, in addition to</LI>
<LI>crocodile tears and</LI>
<LI>anxiety during follow-up</LI>
</UL>
<P>Follow-up up to 9 months</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-04-20 18:58:30 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Not stated</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-04-20 18:58:30 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Not stated</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-06-09 23:36:13 +0100" MODIFIED_BY="Ruth  Brassington">
<P>1 October 1989 to 31 December 1990</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-07-12 12:48:47 +0100" MODIFIED_BY="[Empty name]">
<P>Good recovery defined as grade I or II of the House-Brackmann scale</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-12 17:05:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Engstr_x00f6_m-2008">
<CHAR_METHODS MODIFIED="2015-10-16 15:46:04 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Randomised, placebo-controlled trial with 4 treatment groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-12 17:05:16 +0100" MODIFIED_BY="[Empty name]">
<P>829 participants randomised within 72 hours of facial palsy onset</P>
<P>No contraindications to corticosteroid or antiviral use</P>
<P>Sex: male 341 (41%), female 488 (59%)</P>
<P>Age: mean 40 years, range 31-54 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-12 12:30:06 +0100" MODIFIED_BY="[Empty name]">
<P>Participants allocated into 1 of 4 treatment groups:</P>
<UL>
<LI>prednisolone with placebo</LI>
<LI>valaciclovir with prednisolone</LI>
<LI>valaciclovir with placebo</LI>
<LI>double placebo</LI>
</UL>
<P>Dosages: valaciclovir 1000 mg 3 times daily for 7 days; prednisolone 60 mg daily for 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-12 12:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome:</P>
<UL>
<LI>recovery of facial function, as assessed at visits with the Sunnybrook scale and the House-Brackmann scale</LI>
</UL>
<P>Complete recovery was taken as Sunnybrook scale 100 and House-Brackmann scale grade I</P>
<P>Other outcomes:</P>
<UL>
<LI>degree of pain, as recorded during the first 2 months</LI>
<LI>adverse effects recorded for the first month</LI>
<LI>frequency of severe pain, synkinesis, facial spasm and residual facial symptoms at 12 months</LI>
</UL>
<P>Follow-up at 2 weeks, and 1, 2, 3, 6 and 12 months after randomisation, according to recovery</P>
<P>Final outcomes reported at 12 months</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-12 17:05:17 +0100" MODIFIED_BY="[Empty name]">
<P>Uppsala University; GlaxoSmithKline (Sweden); Pfizer AB (Sweden); Acta Otolaryngologica Foundation; Rosa and Emanuel Nachmanssons Foundation; Stig and Ragna Gorthon Foundation; Torsten Birger Segerfalk Foundation; Margit Arstrups Foundation; County Council of Ska&#778;ne; Helsinki University Central Hospital Research Funds</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-12 10:31:48 +0100" MODIFIED_BY="[Empty name]">
<P>One author was paid by GlaxoSmithKline for a lecture on Bell's Palsy</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-04-20 18:48:46 +0100" MODIFIED_BY="Ruth  Brassington">
<P>May 2001 to September 2006</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-07-12 17:05:18 +0100" MODIFIED_BY="[Empty name]">
<P>Multicentre</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-12 13:01:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lagalla-2002">
<CHAR_METHODS MODIFIED="2016-07-12 12:49:09 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled, double-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-12 13:01:54 +0100" MODIFIED_BY="[Empty name]">
<P>62 participants within 3 days of onset of onset of Bell's palsy; 4 people excluded after randomisation because of acute herpes zoster infection</P>
<P>Sex: male 34, female 28</P>
<P>Age: mean (± SD) 47.5 (± 19) years, range 15 to 84 years</P>
<P>Participants with contraindications to corticosteroids (peptic ulcer disease, pregnancy, severe hypertension), or previously treated excluded. No losses to follow-up</P>
<P>34 cases left palsy, 28 cases right palsy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-12 12:31:00 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Prednisone: 1 g daily intravenously in saline solution for 3 days and then 0.5 g for the other 3 days</LI>
<LI>Placebo: saline solution</LI>
</UL>
<P>All participants received intramuscular vitamins for 15 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-12 12:31:03 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome:</P>
<UL>
<LI>recovery of facial function</LI>
</UL>
<P>Used House-Brackmann scale for assessment. "Good recovery" was grades I or II</P>
<P>Secondary outcomes:</P>
<UL>
<LI>motor synkinesis and crocodile tears</LI>
</UL>
<P>Follow-up at 1, 3, 6 and 12 months</P>
<P>Final outcomes reported at 6 and 12 months</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-01-27 00:58:39 +0000" MODIFIED_BY="[Empty name]">
<P>Not stated </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-01-27 00:58:42 +0000" MODIFIED_BY="[Empty name]">
<P>Not stated</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-07-12 12:31:06 +0100" MODIFIED_BY="[Empty name]">
<P>Not stated</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-09-14 10:26:10 +0100" MODIFIED_BY="[Empty name]">
<P>Single centre</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-12 13:02:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-May-1976">
<CHAR_METHODS MODIFIED="2016-07-12 12:31:18 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled, randomised trial with 2 treatment groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-12 12:31:22 +0100" MODIFIED_BY="[Empty name]">
<P>51 participants within 2 days of onset of Bell's palsy</P>
<P>People with chronic otitis, trauma, loss of lacrimation, and bilateral or recurrent palsy, and herpes zoster excluded</P>
<P>Sex: male 28, female 23</P>
<P>Age: ranges not clearly stated "30 years or less and 31 years or older"</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-09 23:38:02 +0100" MODIFIED_BY="Ruth  Brassington">
<UL>
<LI>Prednisone: 410 mg in descending doses over 10 days, plus vitamins</LI>
<LI>Placebo: vitamins alone</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-12 12:31:25 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome:</P>
<UL>
<LI>complete recovery of facial function</LI>
</UL>
<P>Assessment made clinically using photographs (examples given in the paper) at 6 months after onset</P>
<P>Secondary outcomes:</P>
<UL>
<LI>pain</LI>
<LI>taste</LI>
<LI>hyperacusis</LI>
<LI>time to recovery</LI>
</UL>
<P>No adverse effects reported</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-06-22 00:56:43 +0100" MODIFIED_BY="[Empty name]">
<P>Not stated</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-01-27 01:10:30 +0000" MODIFIED_BY="[Empty name]">
<P>Not stated</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-07-12 13:02:06 +0100" MODIFIED_BY="[Empty name]">
<P>1972 to 1974</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-10-15 21:47:33 +0100" MODIFIED_BY="Ruth Brassington">
<P>Single centre</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-12 13:00:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sullivan-2007">
<CHAR_METHODS MODIFIED="2015-10-15 21:47:12 +0100" MODIFIED_BY="Ruth Brassington">
<P>Double-blind, placebo-controlled, randomised, factorial trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-12 12:31:43 +0100" MODIFIED_BY="[Empty name]">
<P>552 participants randomised and 496 included in final outcome assessment</P>
<P>Referred for assessment and treatment within 72 hours of paralysis onset.</P>
<P>All participants aged &#8805; 16 years and no contraindications to corticosteroids or antiviral therapy</P>
<P>Sex: male 253 (51%), female 243 (49%)</P>
<P>Age: mean (± SD) 44 (± 16.4) years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-12 12:31:53 +0100" MODIFIED_BY="[Empty name]">
<P>Participants allocated to 1 of 4 treatment groups to receive:</P>
<UL>
<LI>aciclovir</LI>
<LI>prednisolone</LI>
<LI>aciclovir with prednisolone</LI>
<LI>placebo</LI>
</UL>
<P>Participants received prednisolone 25 mg twice daily for 10 days or aciclovir 400 mg 5 times daily for 10 days, both treatments or neither treatment, depending on allocation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-12 12:31:56 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome:</P>
<UL>
<LI>recovery rated on House-Brackmann scale, where recovery was grade I</LI>
</UL>
<P>Secondary outcomes:</P>
<UL>
<LI>health-related quality of life</LI>
<LI>Health Utilities Index Mark 3</LI>
<LI>facial appearance (Derriford Appearance Scale)</LI>
<LI>pain</LI>
<LI>adverse effects</LI>
<LI>frequency of incomplete recovery at end of study</LI>
</UL>
<P>Follow-up at 3 and 9 months</P>
<P>Final outcomes reported at 9 months</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-12 13:00:31 +0100" MODIFIED_BY="[Empty name]">
<P>Supported by a grant (02/09/04) from the Health Technology Assessment Programme of the National Institute for Health Research (Department of Health, England). The Scottish Executive (Chief Scientist Office and National Health Service Education for Scotland) funded the Scottish School of Primary Care during the study. Practices were reimbursed for their contributions through national Support for Science mechanisms</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-12 13:00:40 +0100" MODIFIED_BY="[Empty name]">
<P>Drs Sullivan and Donnan reported receiving grant support from GlaxoSmithKline for projects unrelated to the trial. No other potential conflict of interest relevant to this article reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-03-29 12:03:44 +0100" MODIFIED_BY="Ruth  Brassington">
<P>June 2004 to June 2006</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-10-15 21:46:56 +0100" MODIFIED_BY="Ruth Brassington">
<P>Multicentre: 17 hospitals</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-12 17:05:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taverner-1954">
<CHAR_METHODS MODIFIED="2016-07-12 12:32:18 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-12 13:02:25 +0100" MODIFIED_BY="[Empty name]">
<P>26 participants within 10 days of onset of Bell's palsy</P>
<P>Sex: male 13 and female 13</P>
<P>Age: range 12 to 76 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-12 17:05:23 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Cortisone acetate: orally in descending doses over 8 days (200 mg in divided doses daily for the first 3 days, 100 mg daily for 3 days and 50 mg daily for 2 days)</LI>
<LI>Placebo: same number of lactose tablets for the same period</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-12 12:32:23 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes:</P>
<UL>
<LI>recovery of facial function (clinical assessment)</LI>
<LI>signs of denervation on electromyographic examination</LI>
</UL>
<P>Secondary outcome:</P>
<UL>
<LI>duration of recovery</LI>
</UL>
<P>Final outcome reported at 157 days</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-03-29 14:34:18 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Medical Research Council supplied cortisone acetate</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-01-27 01:29:04 +0000" MODIFIED_BY="[Empty name]">
<P>Not stated </P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-06-28 22:48:53 +0100" MODIFIED_BY="Ruth  Brassington">
<P>August 1953 to June 1954</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-07-12 12:32:26 +0100" MODIFIED_BY="[Empty name]">
<P>Single-centre study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-12 17:05:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Unuvar-1999">
<CHAR_METHODS MODIFIED="2014-09-14 12:07:22 +0100" MODIFIED_BY="Ruth Brassington">
<P> Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-12 13:02:30 +0100" MODIFIED_BY="[Empty name]">
<P>42 children within 3 days of onset of Bell's palsy</P>
<P>Sex: male 21, female 21</P>
<P>Age: mean (± SD) 56.9 (± 4.7) months, range 24 to 74 months</P>
<P>Children with chronic neurological conditions, other reasons for facial palsy and acute otitis media excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-12 13:02:39 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Oral methylprednisolone: 1 mg/kg daily, for 10 days, and then withdrawn in 3 to 5 days</LI>
<LI>Control: no specific treatment (no placebo used)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-12 12:32:57 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome:</P>
<UL>
<LI>recovery of facial motor function (House-Brackmann scale)</LI>
</UL>
<P>Secondary outcome:</P>
<UL>
<LI>adverse effects</LI>
</UL>
<P>Follow-up at 4, 6 and 12 months</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-01-27 01:42:45 +0000" MODIFIED_BY="[Empty name]">
<P>Not stated </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-01-27 01:42:51 +0000" MODIFIED_BY="[Empty name]">
<P>Not stated</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-01-27 01:42:55 +0000" MODIFIED_BY="[Empty name]">
<P>Not stated </P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-07-12 17:05:24 +0100" MODIFIED_BY="[Empty name]">
<P>Single-centre study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>n: number of participants; SD: standard deviation.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-07-12 12:33:24 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-07-12 12:33:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Akpinar-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-12 12:33:11 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation to treatment group was according to the day of admission, which is a method that is highly susceptible to bias. It was not clear who diagnosed participants with Bell's palsy and they used varying dosage regimens of corticosteroids. Follow-up 3 weeks</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-12 12:33:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bento-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-12 12:33:15 +0100" MODIFIED_BY="[Empty name]">
<P>Did not provide the number of participants and outcome events by treatment groups. 50% of participants lost to follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-12 12:33:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brown-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-12 12:33:24 +0100" MODIFIED_BY="[Empty name]">
<P>Not randomised or quasi-randomised. There was no placebo group or open control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-12 12:33:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martinez-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-12 12:33:22 +0100" MODIFIED_BY="[Empty name]">
<P>Not randomised or quasi-randomised. 27% of participants lost to follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-15 22:06:27 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Wolf-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-15 22:06:27 +0100" MODIFIED_BY="Ruth Brassington">
<P>Unable to extract complete information on the specified outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-09-14 15:56:59 +0100" MODIFIED_BY="Ruth Brassington" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2016-07-12 17:05:26 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2016-07-12 17:05:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Babl-2015">
<CHAR_STUDY_NAME MODIFIED="2016-07-12 10:32:29 +0100" MODIFIED_BY="[Empty name]">
<P>Bell's palsy in children: a multi-centre, double-blind, randomised, placebo-controlled trial to determine whether prednisolone improves recovery at 1 month</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-07-12 12:33:31 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised control trial (computer-generated randomisation schedule), parallel assignment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-12 12:33:44 +0100" MODIFIED_BY="[Empty name]">
<P>Participants aged 6 months to 18 years, weight &#8805; 5 kg, diagnosed with Bell's palsy by their treating doctor and have an acute onset of symptoms of Bell's palsy for &lt; 72 hours prior to randomisation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-12 12:33:48 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Prednisolone 1 mg/kg/day (dosing based on weight categories) up to a maximum of 50 mg/day for 10 days</LI>
<LI>Placebo: oral liquid with the same ingredients as the intervention solution minus the active drug</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-12 12:33:55 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome:</P>
<UL>
<LI>complete recovery at 1-month post-randomisation, where recovery was defined as a House-Brackmann facial grading score of I. Recovery assessed by a specialist clinician in a face-to-face setting</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2016-01-25 23:51:32 +0000" MODIFIED_BY="Ruth Brassington">
<P> 1 July 2015</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2016-07-12 17:05:26 +0100" MODIFIED_BY="[Empty name]">
<P>Prof Franz Babl</P>
<P>Emergency Research Department, Murdoch Children's Research Institute, Royal Children's Hospital, VIC, Australia</P>
<P>+61399366748</P>
<P>franz.babl@rch.org.au</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2016-07-12 12:34:01 +0100" MODIFIED_BY="[Empty name]">
<P>www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12615000563561</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-07-12 17:05:21 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-07-12 17:05:21 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-29 09:36:20 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Austin-1993">
<DESCRIPTION>
<P>Stated to be randomised at the pharmacy but details not given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-12 12:30:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Engstr_x00f6_m-2008">
<DESCRIPTION>
<P>Generated by computer number generator. Sequentially numbered identical containers allocated to participants on entry into the trial, by the recruiting physician</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-15 21:48:09 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Lagalla-2002">
<DESCRIPTION>
<P>Random list used to generate random sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-15 21:47:28 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-May-1976">
<DESCRIPTION>
<P>Random stratified sequence generated by a statistician, administered in a pharmacy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-12 17:05:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sullivan-2007">
<DESCRIPTION>
<P>Quote: "... patient was randomly assigned to a study group by an independent, secure, automated telephone randomisation service"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-15 21:46:21 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Taverner-1954">
<DESCRIPTION>
<P>Randomisation centralised in pharmacy, in accordance with a master sheet of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-15 21:45:57 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Unuvar-1999">
<DESCRIPTION>
<P>Computer-generated random sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-07-12 12:33:02 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-11 16:12:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Austin-1993">
<DESCRIPTION>
<P>Allocation of participants not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-12 12:30:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Engstr_x00f6_m-2008">
<DESCRIPTION>
<P>Allocation sequence double-blind and generated by a computer number generator in random permuted blocks of 8</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-27 01:00:56 +0000" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Lagalla-2002">
<DESCRIPTION>
<P>Not stated by authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-12 12:31:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-May-1976">
<DESCRIPTION>
<P>Allocation of treatment group unknown to both participants and physicians</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-29 14:34:03 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Sullivan-2007">
<DESCRIPTION>
<P>All parties blinded to allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-27 01:33:31 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Taverner-1954">
<DESCRIPTION>
<P>Central allocation in pharmacy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-12 12:33:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Unuvar-1999">
<DESCRIPTION>
<P>Participants allocated to groups by concealed computer-generated random sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2016-03-03 09:23:06 +0000" MODIFIED_BY="Ruth  Brassington" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2016-07-12 12:48:51 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-07-12 12:48:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Austin-1993">
<DESCRIPTION>
<P>Quote: "The study was blinded to both the patient and the clinical investigators". Further details of blinding not given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-27 00:53:53 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Engstr_x00f6_m-2008">
<DESCRIPTION>
<P>Study drugs issued in identical containers. All participants blinded to treatment group until study completion. All study personnel and data analysts blinded to treatment group until study completion</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-27 01:00:41 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Lagalla-2002">
<DESCRIPTION>
<P>Participants were blinded to the treatment. Saline solution was used as a placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-27 01:11:00 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-May-1976">
<DESCRIPTION>
<P>Double-blinded. Placebo was similar-looking tablets containing vitamins</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-27 01:19:29 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Sullivan-2007">
<DESCRIPTION>
<P>Participants not receiving active drug received placebo. All administered medication was identical and in identical containers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-07-12 12:32:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taverner-1954">
<DESCRIPTION>
<P>Assessors and participants both blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-07-12 12:33:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Unuvar-1999">
<DESCRIPTION>
<P>Participants not blinded to the treatment that they were receiving</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2016-07-12 12:48:50 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-07-12 12:48:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Austin-1993">
<DESCRIPTION>
<P>Quote: "The study was blinded to both the patient and the clinical investigators". Further details of blinding not given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-01-27 00:53:53 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Engstr_x00f6_m-2008">
<DESCRIPTION>
<P>All study personnel and data analysts blinded to treatment group until study completion</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-01-27 01:00:45 +0000" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Lagalla-2002">
<DESCRIPTION>
<P>Not stated if assessors were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-01-27 01:18:03 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-May-1976">
<DESCRIPTION>
<P>Assessors blinded to treatment group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-29 14:02:36 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Sullivan-2007">
<DESCRIPTION>
<P>Assessors blinded to treatment group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-07-12 12:32:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taverner-1954">
<DESCRIPTION>
<P>Assessors and participants both blinded (the point to which assessors were blinded was not clear)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-07-12 12:33:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Unuvar-1999">
<DESCRIPTION>
<P>Assessors not blinded to the treatment that participants were receiving</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-07-12 17:03:19 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-12 17:02:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Austin-1993">
<DESCRIPTION>
<P>107 participants randomised, 31 did not attend for follow-up assessment. 76 allocated to prednisone or placebo</P>
<P>Analysis 6 months after resolution of Bell's palsy included 53 participants (23 prednisolone and 30 placebo), representing over 50% loss to follow-up at this point. Reasons for additional drop-outs at 6 months not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-12 12:30:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Engstr_x00f6_m-2008">
<DESCRIPTION>
<P>Numbers lost to follow-up and reasons given:</P>
<UL>
<LI>213 randomised to corticosteroids: 3 did not receive the drug, 24 lost to follow-up at 12 months (12.7%); 210 analysed</LI>
<LI>209 randomised to placebo: 3 did not receive the placebo; 18 lost to follow-up at 12 months; 206 analysed</LI>
</UL>
<P>'Modified' intention-to-treat analyses used. All randomised participants who received at least 1 dose of study medication included, but participants who did not start therapy excluded. Last observation carried forward method used for the modified intention-to-treat analysis, and missing data points imputed in the post-baseline follow-up visits from the last observation available for each participant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-12 12:31:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lagalla-2002">
<DESCRIPTION>
<P>Numbers lost to follow-up and reasons given: 62 people randomised, 4 excluded after randomisation (2 in each group) because of herpes zoster infection; the remaining 58 completed study</P>
<P>Trial authors stated: "Comparative statistics was carried out on an intention-to-treat basis, by assuming that drop-outs had a poor outcome. Data analysis concerning basal features included all patients enrolled. The analysis of clinical grading changes included data from only 58 subjects"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-12 12:31:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-May-1976">
<DESCRIPTION>
<P>No information on loss to follow-up rates</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-12 17:03:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sullivan-2007">
<DESCRIPTION>
<P>Frequency and reason for drop-outs documented:</P>
<P>138 assigned to prednisolone, of whom 127 completed the trial: 3 received an incorrect drug and 11 were lost to follow-up (4 withdrew consent, 2 sought active treatment, 1 did not provide primary outcome data, 4 could not be contacted after the 1st visit)</P>
<P>141 assigned to placebo of whom 122 completed the trial: 19 were lost to follow-up (6 withdrew consent, 3 could not be contacted, 3 sought active treatment, 1 did not provide primary outcome data, 3 could not be contacted after the 1st visit, 2 died, 1 withdrawn by investigator)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-12 12:32:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taverner-1954">
<DESCRIPTION>
<P>2 people excluded from analysis because of herpes of the external meatus</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-15 21:45:51 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Unuvar-1999">
<DESCRIPTION>
<P>Losses to follow-up not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-07-12 12:32:42 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-15 21:49:00 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Austin-1993">
<DESCRIPTION>
<P>All primary outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-12 12:30:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Engstr_x00f6_m-2008">
<DESCRIPTION>
<P>All primary outcomes reported. Other outcomes reported in another paper due to space constrictions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-12 12:31:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lagalla-2002">
<DESCRIPTION>
<P>Primary and secondary outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-12 12:31:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-May-1976">
<DESCRIPTION>
<P>Primary outcomes reported, adverse effects not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-29 14:34:11 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Sullivan-2007">
<DESCRIPTION>
<P>All planned outcome measures reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-12 12:32:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Taverner-1954">
<DESCRIPTION>
<P>Adverse effects not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-15 21:45:49 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Unuvar-1999">
<DESCRIPTION>
<P>Outcomes given by authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-07-12 12:29:57 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-12 12:29:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Austin-1993">
<DESCRIPTION>
<P>Single-centre study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-27 00:55:11 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Engstr_x00f6_m-2008">
<DESCRIPTION>
<P>No other biases identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-27 01:00:56 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Lagalla-2002">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-27 01:11:19 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-May-1976">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-15 21:46:40 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Sullivan-2007">
<DESCRIPTION>
<P>No other potential sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-27 01:34:06 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Taverner-1954">
<DESCRIPTION>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-15 21:45:47 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Unuvar-1999">
<DESCRIPTION>
<P>No other potential biases were identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-07-12 17:05:28 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-07-12 17:05:28 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2015-10-15 18:40:20 +0100" MODIFIED_BY="Ruth Brassington">Corticosteroids compared to placebo or no treatment for Bell's palsy</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Corticosteroids compared to placebo or no treatment for Bell's palsy </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with Bell's palsy<BR/>
<B>Settings:</B> primary and secondary care<BR/>
<B>Intervention:</B> corticosteroids<BR/>
<B>Comparison: </B>placebo or no treatment</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo or no treatment</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Corticosteroids</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Incomplete recovery &#8805; 6 months after randomisation</B>
<BR/>House-Brackmann grading system and Sunnybrook scale<BR/>Follow-up: 157 days to 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>281 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>177 per 1000</B>
<BR/>(140 to 225)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 0.63 </B>
<BR/>(0.50 to 0.80)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>895<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NNTB 10,</P>
<P>95% CI 6 to 20</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Cosmetically disabling persistent sequelae </B>&#8805; <B>6 months after randomisation</B>
<BR/>Clinical assessment<BR/>Follow-up: mean 6 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>216 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>208 per 1000</B>
<BR/>(86 to 495)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.96 </B>
<BR/>(0.4 to 2.29)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>75<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Motor synkinesis and crocodile tears</B>
<BR/>Clinical assessment<BR/>Follow-up: 9 to 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>260 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>167 per 1000</B>
<BR/>(117 to 237)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.64 </B>
<BR/>(0.45 to 0.91)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>485<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects</B>
<BR/>Follow-up: 9 to 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>127 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>133 per 1000</B>
</P>
<P>(91 to 192)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.04 </B>
<BR/>(0.71 to 1.51)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>715<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>3 other studies recorded that no adverse effects occurred with corticosteroid treatment</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>NNTB:</B> number needed to treat for an additional beneficial outcome; <B>RR:</B> risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Two trials excluded participants who were found to have clinical evidence of herpes zoster infection (<LINK REF="STD-Lagalla-2002" TYPE="STUDY">Lagalla 2002</LINK>; <LINK REF="STD-Taverner-1954" TYPE="STUDY">Taverner 1954</LINK>). In addition, two studies did not use a scoring system such as the House-Brackmann or Sunnybrook scale to assess facial motor function, relying upon clinical examination, electromyographic tests or photographs (<LINK REF="STD-May-1976" TYPE="STUDY">May 1976</LINK>; <LINK REF="STD-Taverner-1954" TYPE="STUDY">Taverner 1954</LINK>). <LINK REF="STD-Taverner-1954" TYPE="STUDY">Taverner 1954</LINK> reported outcomes at five months rather than at six months or more. However, we felt that these limitations did not compromise the generalisability of the findings.</P>
<P>
<SUP>2</SUP> We downgraded twice: first for imprecision - there was a low number of events and pooled RR allowed the possibility of both no effect and the chance of harm; second for publication bias - of the seven included studies, five did not provide data on the presence of cosmetically disabling sequelae six months or more after randomisation.</P>
<P>
<SUP>3</SUP> We downgraded once for imprecision. There was a low number of events.</P>
<P>
<SUP>4</SUP> We downgraded the quality of the evidence to moderate because of publication bias.</P>
<P>
<SUP>5</SUP> We downgraded for publication bias - only three of seven studies provided data on adverse effects.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-07-12 12:49:37 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2016-07-12 12:49:37 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Corticosteroid (OS) versus placebo or no treatment (OO)</NAME>
<DICH_OUTCOME CHI2="7.321430213231051" CI_END="0.8038672523876791" CI_START="0.4954345976650204" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6310813329221323" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="125" I2="18.04879886504969" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.0948156630866672" LOG_CI_START="-0.3050136686214925" LOG_EFFECT_SIZE="-0.19991466585407985" METHOD="MH" MODIFIED="2016-07-12 12:38:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2921415726792591" P_Q="1.0" P_Z="1.9288548127025846E-4" Q="0.0" RANDOM="NO" SCALE="231.72" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="450" TOTAL_2="445" WEIGHT="100.0" Z="3.72815664029161">
<NAME>Incomplete recovery &#8805; 6 months after randomisation</NAME>
<GROUP_LABEL_1>OS</GROUP_LABEL_1>
<GROUP_LABEL_2>OO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OO</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6462471549278392" CI_START="0.2583638863589022" EFFECT_SIZE="0.6521739130434783" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.21649503741542397" LOG_CI_START="-0.5877681913392473" LOG_EFFECT_SIZE="-0.18563657696191163" MODIFIED="2016-06-28 17:03:58 +0100" MODIFIED_BY="Ruth  Brassington" ORDER="66" O_E="0.0" SE="0.4724282017376837" STUDY_ID="STD-Austin-1993" TOTAL_1="23" TOTAL_2="30" VAR="0.22318840579710153" WEIGHT="6.907493950165091"/>
<DICH_DATA CI_END="0.9107280338356419" CI_START="0.49568004392009674" EFFECT_SIZE="0.6718851924331376" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="73" LOG_CI_END="-0.040611294858503295" LOG_CI_START="-0.3047985654399027" LOG_EFFECT_SIZE="-0.172704930149203" MODIFIED="2014-09-14 16:40:59 +0100" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.15518491048759447" STUDY_ID="STD-Engstr_x00f6_m-2008" TOTAL_1="210" TOTAL_2="206" VAR="0.024082356443042706" WEIGHT="58.656665547341504"/>
<DICH_DATA CI_END="1.5723688678825776" CI_START="0.2164109101422309" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.19655443641957582" LOG_CI_START="-0.6647208484863117" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2016-06-29 10:10:01 +0100" MODIFIED_BY="Ruth  Brassington" ORDER="22" O_E="0.0" SE="0.5059173657351376" STUDY_ID="STD-Lagalla-2002" TOTAL_1="30" TOTAL_2="28" VAR="0.255952380952381" WEIGHT="6.586456000457268"/>
<DICH_DATA CI_END="2.3594332848777335" CI_START="0.5659446488839817" EFFECT_SIZE="1.1555555555555554" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.3728077017810706" LOG_CI_START="-0.2472260420621597" LOG_EFFECT_SIZE="0.06279082985945544" MODIFIED="2015-11-10 12:41:02 +0000" MODIFIED_BY="Ruth  Brassington" ORDER="25" O_E="0.0" SE="0.36421089035004517" STUDY_ID="STD-May-1976" TOTAL_1="25" TOTAL_2="26" VAR="0.13264957264957264" WEIGHT="7.022324412252235"/>
<DICH_DATA CI_END="0.696318112926545" CI_START="0.10225852534169608" EFFECT_SIZE="0.2668416447944007" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="18" LOG_CI_END="-0.15719230762244174" LOG_CI_START="-0.9903004744745502" LOG_EFFECT_SIZE="-0.5737463910484959" MODIFIED="2015-07-11 13:00:52 +0100" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.4893718611608647" STUDY_ID="STD-Sullivan-2007" TOTAL_1="127" TOTAL_2="122" VAR="0.23948481849604863" WEIGHT="14.61320328294224"/>
<DICH_DATA CI_END="2.71139883043415" CI_START="0.270964886944862" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.43319340438132603" LOG_CI_START="-0.5670869836425524" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2015-11-10 12:41:01 +0000" MODIFIED_BY="Ruth  Brassington" ORDER="28" O_E="0.0" SE="0.5875696513930032" STUDY_ID="STD-Taverner-1954" TOTAL_1="14" TOTAL_2="12" VAR="0.3452380952380953" WEIGHT="3.4283347899816037"/>
<DICH_DATA CI_END="2.605831928792184" CI_START="0.007831726612838538" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.41594640111102243" LOG_CI_START="-2.106142481139536" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2016-06-28 17:04:00 +0100" MODIFIED_BY="Ruth  Brassington" ORDER="29" O_E="0.0" SE="1.4814874939752933" STUDY_ID="STD-Unuvar-1999" TOTAL_1="21" TOTAL_2="21" VAR="2.1948051948051948" WEIGHT="2.785522016860053"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.051933269935101785" CI_END="2.28904165055752" CI_START="0.4048969174207746" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.962717979555021" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.3596536950086326" LOG_CI_START="-0.3926555296090717" LOG_EFFECT_SIZE="-0.016500917300219513" METHOD="MH" MODIFIED="2016-07-12 12:38:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8197327514229238" P_Q="1.0" P_Z="0.9314835205201781" Q="0.0" RANDOM="NO" SCALE="25.95" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="37" WEIGHT="100.0" Z="0.085978484809192">
<NAME>Cosmetically disabling persistent sequelae &#8805; 6 months after randomisation</NAME>
<GROUP_LABEL_1>OS</GROUP_LABEL_1>
<GROUP_LABEL_2>OO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OO</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.377830112419276" CI_START="0.2119633929274639" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5286378029927664" LOG_CI_START="-0.67373913728999" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="1" O_E="0.0" SE="0.7062821665839359" STUDY_ID="STD-Taverner-1954" TOTAL_1="13" TOTAL_2="11" VAR="0.4988344988344987" WEIGHT="39.867708959711365"/>
<DICH_DATA CI_END="3.160106648667351" CI_START="0.342266929648125" EFFECT_SIZE="1.04" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4997017396266829" LOG_CI_START="-0.4656350610291221" LOG_EFFECT_SIZE="0.01703333929878037" ORDER="5" O_E="0.0" SE="0.5670436151994497" STUDY_ID="STD-May-1976" TOTAL_1="25" TOTAL_2="26" VAR="0.32153846153846155" WEIGHT="60.13229104028864"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.41751790608599554" CI_END="0.9050725770409924" CI_START="0.4481111355358098" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6368462139639057" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="64" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.0433165936736828" LOG_CI_START="-0.348614263760096" LOG_EFFECT_SIZE="-0.1959654287168894" METHOD="MH" MODIFIED="2016-07-11 20:51:15 +0100" MODIFIED_BY="Anne Lawson" NO="3" P_CHI2="0.8115909397256726" P_Q="1.0" P_Z="0.011864949199114112" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="239" TOTAL_2="246" WEIGHT="100.00000000000001" Z="2.5161356940021244">
<NAME>Motor synkinesis and crocodile tears</NAME>
<GROUP_LABEL_1>OS</GROUP_LABEL_1>
<GROUP_LABEL_2>OO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OS</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.9469145145789226" CI_START="0.24246644445619375" EFFECT_SIZE="0.9782608695652174" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5962577202012653" LOG_CI_START="-0.6153483560137262" LOG_EFFECT_SIZE="-0.009545317906230389" MODIFIED="2016-06-28 08:05:58 +0100" MODIFIED_BY="Ruth  Brassington" ORDER="67" O_E="0.0" SE="0.7117034067154904" STUDY_ID="STD-Austin-1993" TOTAL_1="23" TOTAL_2="30" VAR="0.5065217391304347" WEIGHT="5.47330442708002"/>
<DICH_DATA CI_END="0.9005872318155097" CI_START="0.41353497112506443" EFFECT_SIZE="0.6102657739906675" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="53" LOG_CI_END="-0.045474214592024914" LOG_CI_START="-0.38348775787821404" LOG_EFFECT_SIZE="-0.21448098623511952" MODIFIED="2014-09-13 12:43:25 +0100" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.1985508285203317" STUDY_ID="STD-Engstr_x00f6_m-2008" TOTAL_1="186" TOTAL_2="188" VAR="0.03942243150611016" WEIGHT="83.11030159364701"/>
<DICH_DATA CI_END="1.8591540238169142" CI_START="0.23905735552344556" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.2693153709030606" LOG_CI_START="-0.621497889014423" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2016-06-28 16:40:15 +0100" MODIFIED_BY="Ruth  Brassington" ORDER="9" O_E="0.0" SE="0.5232681184722836" STUDY_ID="STD-Lagalla-2002" TOTAL_1="30" TOTAL_2="28" VAR="0.27380952380952384" WEIGHT="11.41639397927298"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.310389600678085" CI_END="1.5120902789122261" CI_START="0.7129757593933013" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.038308102096229" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="45" I2="13.434513407911265" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.17957772136555053" LOG_CI_START="-0.1469252355628463" LOG_EFFECT_SIZE="0.01632624290135211" METHOD="MH" MODIFIED="2016-07-12 12:38:21 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.31499621221874885" P_Q="1.0" P_Z="0.8446026948327056" Q="0.0" RANDOM="NO" SCALE="224.34" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="362" TOTAL_2="353" WEIGHT="100.0" Z="0.19600954546038193">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>OS</GROUP_LABEL_1>
<GROUP_LABEL_2>OO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OO</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.436403811522334" CI_START="0.4815951030399828" EFFECT_SIZE="0.8317241379310345" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="25" LOG_CI_END="0.15727654886347656" LOG_CI_START="-0.31731793772516126" LOG_EFFECT_SIZE="-0.08002069443084238" MODIFIED="2014-09-13 16:41:12 +0100" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.27877915070276316" STUDY_ID="STD-Engstr_x00f6_m-2008" TOTAL_1="203" TOTAL_2="201" VAR="0.07771781486655394" WEIGHT="54.56824516932726"/>
<DICH_DATA CI_END="122.21032565718947" CI_START="0.35382106595826235" EFFECT_SIZE="6.575757575757576" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.087107901376991" LOG_CI_START="-0.45121631343570673" LOG_EFFECT_SIZE="0.817945793970642" MODIFIED="2016-06-29 10:08:09 +0100" MODIFIED_BY="Ruth  Brassington" ORDER="24" O_E="0.0" SE="1.4910242086884862" STUDY_ID="STD-Lagalla-2002" TOTAL_1="32" TOTAL_2="30" VAR="2.2231531908951263" WEIGHT="1.1199258691463532"/>
<DICH_DATA CI_END="1.975935597535748" CI_START="0.6725149237402281" EFFECT_SIZE="1.152755905511811" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="20" LOG_CI_END="0.29577278534743245" LOG_CI_START="-0.1722980738146" LOG_EFFECT_SIZE="0.06173735576641621" MODIFIED="2014-09-13 16:43:07 +0100" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.2749471396598986" STUDY_ID="STD-Sullivan-2007" TOTAL_1="127" TOTAL_2="122" VAR="0.07559592960715977" WEIGHT="44.311828961526395"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-07-12 17:05:22 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-07-12 12:38:52 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram illustrating the study selection process for this update.</P>
<P>1. The previous version of this review listed comparisons involving participants treated with antiviral therapy from <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK> and <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK> as two additional separate studies. These two comparisons are not included in this update.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvoAAAJtCAYAAABHfNQuAABvpklEQVR42uydD2SW3///PyRvSRKZ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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-07-12 17:05:22 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each methodological quality item for each included study. Green (+) = low risk of bias; yellow (?) = unclear risk of bias; red (-) = high risk of bias.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUAAAAInCAIAAABm6xeCAAAayUlEQVR42u3dv27cVtfF4QEMGC5U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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-07-12 17:05:22 +0100" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Corticosteroid (OS) versus placebo or no treatment (OO), outcome: 1.1 Incomplete recovery &#8805; 6 months after randomisation.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAyoAAAGACAMAAAB1D2ZUAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2016-07-12 17:05:22 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.02" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>1.2 Cosmetically disabling persistent sequelae &#8805; 6 months after randomisation.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAyoAAAEwCAMAAABvxXUhAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAA6JUlEQVR42u19C3gc1ZXmkbq7qqu79aiSlNgQiGUpZL+ww2aMsS1L
IqFtEzxkwkwGstm8lkn2M5uBwM4MMx+wOwtkdpcAm50wSYaEPLyEMDMkxAMkDiS2O8GSDNaAk2Vw
ZkL08GNsGSRV6d2Pakl7X/XqrpZaUqstS+cHuavu49xTt+65j6r716lQAYFAzI9KrAIEAk0FgUBT
QSDKi4Cy0jWsr6gIyrVTYFbKwcCtfVOlEQqVgXANkdXxvYqAPBUo90XFGxvPBKRkIN7Yb4f0e+J+
/m1x2vGU6Yosu5LXjkwVVPLaUetu1M9mz5OSVJOzAbnGV0sBbbZSygqdw7VTi1R0xY8qDeMz5yZg
1AR1R026+vWJkgg1x2Ynzs2MN8DAzulzkxAzy39dicxoSxUkEoXidlon926DAsnKoWR1eqqgktXp
SevkipbzpyQk0tXbJucqfmL7uTOWzlsnF6voijeVt1qjWmi4TYU0ZGAokSyJ0No2PaRFW9+Cda0H
iPTW2vNxZQrMQDwOHVFJUrqZAYflbldcd0QKRZIS6Q1pMpiVperyKzkEJi29QZGkKOtQTDlsuuLM
qCQrHbaSd8ryeVCSaDLNtZSl6AAN6JbDDfSX6SO1wY2anTJLU/K6ddX9ajCVW+ANgCS5KSG48rb6
EgnNEolErgxhuJxKz56PK+sANu/btfXcyZb30UZY9amJLa649w1nprapGdIX0pDqHfujm2vKP/0l
9U4w3jJQs5WWbt4K4yFXXM3zmYmWJywla45F9p8HJUl1BenPGNVyI9Xy6or+QVsfSzuekq04eN06
db8qTOVxIB2CBrMwKsOvroiWZqo0y4VWWAez52GKHb/35RfpwQxc9MLTdLCs2v50yB2XfOXOatJb
ClwFm3ohVXYlr+gepQet8Ins03RhEuuJhNxxU5XV1eQeCaSgt5oM/+WvyqNRfnix+QValbHt4fV+
+pCU8hA9EHVr1/0qeQKm0/8rIPTkL7pga2m6rAou1CW9/BPs1zqgmR58vXP7ExfRF8EzRyxLSNxP
4w7e+2gM2p3uUCu/SSd+2Tk9Tg/u7kr/9l1sEtOVseO6SJz632f6iCE5XdAWx7rLpuX+zulf04NI
V8umdtbym01ffRKJ/ekqeiDqdtSq+1VhKik4Tq6cTgM0Y+DVEk2VgnQYPk6Epql0hQ/f5Z5fx7Zt
oL9/eO6Xh7bTDrta3mZ1cO007no4/Wv3jdLPg0nrkRbWknYO7D/aQx+pjIS3NlhxCombhFOyk/xm
quTO8q/6lO2sKo2B+7tbaWca/d7Wen99FG45om4Vq+5Xhamc69qlm8lmA5R4hxaCUEmERpo1U9/V
9Rsi/Sl9WOuMnI8rM15K0r4vcuPz3AaGhjrqvHHpJtqN8+FPgmNNZGlVboy8R6ZKKjeOnGZLK6Wv
037sNXJEbqiEdx+jvThX8iloOgZHyl+Vo0dSA0zL3z/FtNQHuZb5+tRbLYjVbeTGQLbo/qdixe8B
q0+aFYHoIJhqpmI2nS2NrTRMTs+GlCEmHYKjoXJfVJwuNGuuPLoVEuaffo1eHw2JbXltyImTb3xc
3gwJbSKQJEH6hqs6lNHyK6n+NlWy+5rsbDAyREOiW+9vd+LkqZkwUzI0yZRMVchj56Eqazd1b6Fa
mhCKDDpaCn3ifFkfB+iE0EiInCZrgdatqPvVYioIxIoAbmxBINBUEAg0FQQCTQWBQFNBINBUEIjV
DRdfRf9qReD9b3V9g3IPXJhjd3/3YzvPBMM222MphIV4I4Vv/hx9/NJTToefEnNJBXNeqd8rIPWp
b+h/9b4zgw929w5kc+PFkSsvl/vUN+q3CdEsiZ2DldnvW3d2oFkDwaxBymNpa6AqBbOpkKidysAf
vxhYGllkpevHC9nV2Dgx5db5bIASmZx2EghkswF3fKg6WbgxxHPaBs2vTAaKMZWLJkbGf3XN57Pb
LvFcVSMUvMi/bX/yoYlrrnt1/pTzohES/f3+2XP04ejvpzmss5Pv6PdVdy6p71i81IdT9+2ES/9j
6On1t71gZcxJedIjvhHg4dRzHcDjWBJbItMRfLW006hX7X16+y0VP1h3w6MkYUX1VNaM8pfMDWOh
M39RNWwupe5Xvn4MPyP6PfId972d1q7ss7tRczZ0ZvfJYdMVP/ilzd/ZW7Ax8AsDT/7fDJnFTMD+
HLKgJGhnwLkH5M+MhlUAJd4AZpxtquB8hHg8xizMhPeQHI9ZqQFqdismdEfCtXEqIhKhG5ukGrAS
xON75cgce4Pr4zHybyxeT7kZOkmuRuUk08fhS+SAyWd0iYaoJIXrfaXSbafReD1JeyeVqkXkvTyL
zW/IAeOGyDQJ52PkROuwHjrJnw7369WSzFQlKeVaVgn1Slhjed04osPvzbXjIx6vlxXQI5Kp3ynJ
szroym7n7XAK2nvhd2Aa7qNnM4PTUCf2uCTbwpqSmFzy7GKl60fwYTgKO7xBg669kLWkpHZvSdoL
cF3R4nn+qaLWKpWwiTYK07W7P7g1otPtRyY8QVuOw0cYZKyyAPy2txnNvtzyN3DVth9xUx8+DTWb
90evdBGn7ohum2Nr4tBLW0wwt7yU2REZ3dxIKz3SegfTx+ZL5IDLZ4SECTlzcvu4r9StROrWl8zN
B2LHqNTp3tbPsiw2vyFXKuOGpGkSzsfIiVcgAw+Tv89BoHFzNLp5A6+r6P38/o1tT6ZdlcibzC1g
zr3beyjccnDjNiXUeCwW2bEBnmh52WkGbCf0Ifg83CSTG1I5UKln+kRfSOk8JcBK148gQ5pgDr29
wxWQ9Snp8gVsr83Op6nLVMaOQMu9UQ8nTIaefwQ4R7S8jXbdzv7/JNuQ/WJujhO98ByEodrg1V9H
0lb3gusWnOgBuWC/FScjVx35T74KepOsmP5BwYWw+RI5cMlPVlZ/On+XOpUqc6lpCPcwxkf/epgR
0YLfkIPNDjfEy8fg6NpuZjtbOrPmrzoHSY308E3opK5aWLQR8tmHrvY0tGpurbw6sknckQ9OHekn
5fb0kgp/DnpP2ClC0Pws+fmvXV+NbLsEwhuUjdL3pVpeMVpJ2uFK148M5ds7dVLzHr3ufflf7DO/
knJoC3HvdXkvk1KXcuILmkro7LEjsNXDCWuj+/1B6coOZI8Mgmv/P9dqy9lXvTk0jRj6DGwJCUVJ
2i2eC9C0ghs5EwS9zWkz3dzXATfeyFqzBoIL4fAlvHDJV6+Y+UeisI/Uvi4itatvGu66kVWdBiKd
w2/I7aw0W6qHj2E1jGCbtEVqC5LuY5aqekhc3BbrsvPUIFOFt8h/Lq28OrJ84e1tksYlTtOqdq73
1A2Tt3YBTKRDvaT3G0n3JU/cPvkRZraCdrNUrHT9KGdCIjWf9eh1/zZnTuBXUg5tIeG9Lu9lVpLU
iWIfFmsjZ38hOsQuNhEjE3Kdlh9qe1cbHVTy9v9ro2ePkTbdafOkqG4B0G3bD/CgDitB99wVp32v
tbb1e1olPJ1IZNwRNl8i96mEw+KYhFMFRlAtTKSGtUCeVJvfkFcpuqWnl48hpqVkBAmSosPkr8IW
WuFk8kGoSz4Syuuvvc8Tk0c60yaXaNI774jT7khPzYas3g/gmKy1hh7nZntZSRriStePUky2xLfA
2z1h7a7xO+hT0mULYCIFKHWpSFMJxzXtOSK7mRnjQD2b3zTTefiPYQswllHO/v9wPKn9kOS4Geo3
8IcKTaRuknDMVlCwLALQwBPsbC44AWPo7dra1UtybTTjNoeE6mPzJXIg5NMepRKqjhWaZndu7Rqi
aRviUSusk0kV/Ia5pL47T2qIjBqDMEQGmxC5mqaBuMInYM2uNU1eHxdsC+R2ZDmtcmfrT6OtQVIu
kRghopsa7TRkNX24jczU5XqFzc5/V7Z4fkpzSk86V7V4rHT9yHiyP/HLnKlth8sUIp15JekpKP7b
XZHO6/TaIk1l/OikdF/3z+HpzkvA6Po07SSyL088Qk2iE44wrnL/K5PXv+KQJg53fzC0s3sEWrom
JG6ZU0cSYLz0RZUONGxt8sr1k6+MgHFk/Me8uImjw3OsVaAuBaE6kuvKaLddDNXnxaMb1r3sU+FC
frTzYjKbir5QQGooDcEQnDh0/ejRESvi653vIFLH1h2N+Ul9YPLVUSLxHRA5MvrhvMlKF8ghCB2B
rjfgxKbJd3KO/PDLk2HrsoHl9eD/+LDSutwnDZuPXG28tKOT1PGGoz+HxEtTFXaanwQiD/xChxcD
YzWb+gHqKwfhyihrBYP7ptfVvDKy9Ja40vUjphKEN8F09UBxeYerTQweyq6vOeQuKb4++8uhudYq
3rtaPbN+6uixwgoUw1fR4aLtrw0VfU1SpK/nrqN+zwfjcL4+FVUGyOH+qg+8tJCPLzWMp0qSZrmw
0vUrM4oxFXm2MrKAxVnHtdOUi+ZnRJBZvTWppbIQeHHLAnJElaGSpFkurHT9VqCpIBAIBGJR+IO1
d8lBHFUQi8Haazcr/0v4iJWIsn/1vnub9FL6Ex85ECjRuX77jV/KDH7kwYcKxKOpIC5MU/nuN59/
5uqTVY+1fHFfSc6Hpmoefe2B2r+56aGHfON9gNQuxAWA7/7Pbx+GDJC/3/12Kc6P/lMPQIb+/dNZ
v3g0FcQSMSZQ5mL1f5DgauB/jwyX4Pw9mzfv+5P3vvfGtzZv7veJn28CZqQYFjgjMxSRVxEiFCe0
lDDm0cyjR4ml+l+Oc81KToAyXwX45LEqjvzkxXqk+eVVeKHLD+ur8nJ5J2CXPX8Y1m88DCevJr8T
Ly75/Pb/8CiMPvfiNfef/BU80P+tvHhfBD3PNIwFP9fg2+0NK6/qDi2ppcyjnVFUqsVJ9b8ckdcR
4QQY6txK5OVxPVDykegp36888qcasIrx/OGrD0uHZ+D99Pf1pZ+Hrnjt0lqIfQj+/lfktyovfj5T
cTcQ+4YZwoTYf+yGOiHsduXexmWCOl+bN4pItUiphm87VEvcERQuwlO+uiwK5JI2C+EZO3VR6Uu1
j+lbbB0BwNYTh2uWfK6wdcrEp+Bv6W++/GJNxd3V2v2aq8d0p1B9jKxQ21pOqMspVS1V059z+FLL
fHFLatWJeFl385G+HlSyhlCHyXri8NLPYaQWXrv0P+37/Ifo7yX58UUu6/mdIa3d8PZg6pz3j/fq
yzgRMIpqf8YCW6mxhJHQymt4KkFlwUZx9UAS8/lXoYrzUc9RmR1ZIlYz3kX6+3e/H+DdlaTf/8zS
z0drATKn/h7+hP6ezo8v+gmY4brPRt49N3xagWp4VirLcueKs8KF2upSbJvlVe2Gah2pC1g8GNxG
1MWpzI4MdZUvVAiepM+mDgN/RvWupZ/L8NrI5it+NVFLf33iizUVWveu+6KquXdKVX1un9eaYLXf
PL9Lt49K11cYuO+ItdL30bXE9kq2lvj9pZ8H2FrlPTH2biWQH1/0qGJNJAo+zjLmflJEbanUt9go
YarFp5/z6ZhR+qvzm36VRPnFolqgzMWG7nTee/xwy9LPtfTmza+NAB1TNqe1/HhfeDe2sIfzipFS
6QH9I8cplR+KP1eIJwsNFD/gii4VHNEF4NajxFL9L8d7zYbiCCMNnNbhvMU6eTwV58QaIF638Pcn
ylx5U+XdoVTmjS37HjiX4e89fviJUpw/NP4/HqitrHzg1KPper94PyBfZWVhjhnX/O9qyoh4ufms
w7GP/+bwZ971+VCpzmfCMHL6XQGtQDyayoo3lcJT1zmNwYBVbirnH0FsnSvrIcGiotYifaTswE34
iAtgrVJ6fsrC+So4AUMsFK59xWV7FPbdf+g5fDX9788+sajzoSR9L0/+3l3ve56b3ge4CR9xAaDU
/BTkqyBWJ0rOT1kiX8WifPisXtxkEEOQWoxUWR/lG3NTaXJ5H6WWqhQTadiUk/kIO3a0ndtixvjy
VdzifMorH1+FIe0cyuUpsdT8lKXyVfK5EXa4E6taG/ENtczP8otjgKjLINX/UvMj7Wqaj6/iVLKd
23AU8mGzGD5X6r0tyFdZCD+lZHwVL2PFZ0+9sejd6YsfVNRiWvxCbbc4qYUv1bvzrejmWmxKdc4w
l5SS34g59QsUma50WpWan7J0voogcOV2o6p/AyvvW6/i9t8udJduken9LzUnVF2MCRZlPPNwy5bh
RqhFPgErUwsoNT+lVHwVf8ZKXidS5kF/3q3mc/M+liTV/1ILVMCC+Crz2uicfJXzciPOB0rNT1kU
XyVY/PhLCcNG2TuUBZWmLovUYmZfOeFiEbPkiaDqIyk3YA28GXuS9vucT3JY8E8WdC6zdyh0XUJ+
U/nnuemLH1UMP0qKzcdYmRyK5dFqcVIX8TWPORk+a4r/49tKS8xPKQFfxXly42GsFLGEK8NSpYjW
aSyL1LLMLv0GBz/+z5q0mVLzU5bMV0kp4n83Y8WKcUgVKTdvolyYpzjB7CgxX2VOqXl8Fbu+5uWr
OASUPIaPh6/ijc3lq3hvy6p+r1JyfkrJ+SpIV11J80jkq5SUn1JSvgpayvmYaCJfZYUiWMLnSYgS
rFoWeTvwXi3/swWsAgQCTQWBQFNBINBUEAg0FQQCTQWBQFNBIBBoKggEmgoCgaaCQKCpIBBoKggE
mgoCgaaCQCDQVBAINBXEssBUo5e2vqh2r7XrRqcRiAWg+wNmelp8/3p9cDAYwlEFgciFnnwk/K6+
029ZX4ofOJ0Ky9UDa9FU4gzWWX3EFcF+tDCYMUme1aGbp6yRawFmkyK9Ikl3mjRtuPwDVUNUkiMN
0B2VpJhZMqn1RJxi5tQLR5Sc6zFZmjXBnJXkmM5mJneS4ruhNvR1kqCj4PzFST8r7Zgl85ja3ZLS
Ie4AdMd20Hrkfbgcd6dnd0WWbmexDRF2rUJGnoKlRsedckPqU7l2MXTuZDigVK+NuZjr40b9/Y2Q
sP2WbXuHfdgI9FA/+y9p9aq9T2+/peIH6254tL8fKqqnsma0gjfWsdCZv6gaNknaSPqtB8tt8GaN
fGXrq9/d9k9v2zRsllDqG91vTvf394+/vTvjtszKraRKLpoYkrePpNW24dDmO2m0WqE/03d3xaeO
HJoe+NJjhaQ66St3jDxy5gtpddOriW/9nckqOgGPtd/zDIzw7wd9jxbjpCeYmanWq/UMOzq5l1yr
kNHP79FyLU7ib/8viYkpgDrRL7p/p8ZHv1wrV40F1uAE7E5ZrgaJ9HFgKrKkWF9/2dgTgBS098Lv
wDTcx+7b4DTUhXlssi2sKYlJerh/e1O5r2IiM3gKniR6KUOQKaVU9u1B0Me7PF/Z+q0s/fcF6Osh
pWWgtxfaaUAGejaBAo+HZuHfFP5AlpNehqFN5NTs1LdkJq1oBTb1imsw0970BKn04DiPTaXX/xpM
S8ayob42vG7i5N++RO0CYLjO//dcqleWqpNrzVRqjkX2b64htZ+Aaj092TJl9S3QAxVAZgKH4PNw
kxzRoXKgUs/0WbFvWALe4/6mWrmw+/qXTsHD0FFf0nYTvvfIKO3tW8OD7uCjzCnaJaBpMEv+Iz+H
aAA7+hSpi5v1dF9BmU56Vpufgo9VROSoNcMi50wqRfCn3vQcTfY920iOhIzlGU0ORlt/0z/wz+Rw
eN6/4TdPplqVGnMtmUoaeqtFY09eUn0bzNimokEImp8lh/+166uRbZdAeIOyUfq+VEtjW0GzH6qR
3r3sePKTLe+EliP3XlGRLaHUs/9++5+SQWVzl3d2M8mutYc35FY7mB09Dkr0yo1yo1xbQKaTPgjN
ZAyCntavRrdeYgUKqXSap1ztTc+7+UkQI1zHFDkSMpYF6/9g5uUFZXh5FtavJVMhvdgW0dhrr/jL
fdBmWwDAqRsmb+0iM5N0qBeyZEbdlzxx++RHaGwX2P2i1SmWFdoNZDi5Zvv+12aDpZR6E3yNzIlm
Zc0nspPXSpcd0MWrbyRzU2ooXZ0qINNJf/rohMbObuiBbI5UapCxnPTMUsbb7uGfLW7Y0XbMIDIm
ta5lqtOh0eT06++86INsjjXfX92677w+mBodWlNrFdB12MkOpuCTv3aZkA7aHemp2ZB1DnBM1lpD
rE8LwWV2dn6nz8OlmHStIpVWKrmWBvBdsu4A3STRFbS+dnAFyBGt0OZgaPvgdEGBVnptMpMklt1l
jyPsOQuN5g9WrojTBaOTnj4TG4f9/N7oY5X7R6iMdLKkvUMO2seSPwy/MyTWJWyu5fNbccnGofQd
7doaW6uEoekYHCG9mw43w2XOCp02wYhkHm6TQZHrFTYN+F0ZmvnsVGlO6cl4lB5WQbDcV6FIDa+T
FW4AkvVQurdiyp6GJvoB62no9R8ejr2N1AqpgmPwY/qUXIKmJvgrOnFV4MhAoTdWTvrIHlNtowKO
KRC2okPQ1AwpGp1IJOiC0UlPcFXFCVrv5OQpqKJHQsayDtjKWHro9UvWWe9Tcn7r/6gxNT1hrG4z
8TeV/lcmr39lFL7e+Q5o6fp39rSKrlPgJ4HIA7/Q4cXAWM0mMn2vrxyEK6Ns6jy4b3pdzSsj9DAL
Xyn3VcRCo7uIzi9214x1j5ZMavTJ0U2vjNEL8m0HJ7qvnzw0DEOHJq7vZnOioU2Tk91XkkVEYJCu
4wpNa+z0PzkdTZI51Ngr19ccsj1AH+yenNiU9UnPZmbh7R8Xr1D+uPW36JGQsezz2/aJ9OzGS96W
E1y3rvay6a+MrIe1gOI3tujrw8W1wurMWQ0QiwAZSQrG1U8mF5u1lA/F3paafpOYCLXst0tSz1q6
0QvYA9ZxbXEPziNhHVv9oiBBRcHn7NGhuRyoyLPL+XLFi+5dZvriM1X/vH6N3R3cLolY1AC49pxG
4HZJBAJNBYFAU0Eg0FQQCDQVBAJNBYFY3XDtQRHvfK2nx45D2/k8DZfFE7GxLK5BDXQ4ili4qagr
2f22sSzaGSq6HEcsYQJmGAbtbw1xlBMMTgRJ45sSgVjVo4q3q1XJj6fTdZ9YxyxNXkoEYm2YimdK
lhdkqC6TUOdJXTqoy7KqUHGtgiiJqYBR6MQod5vDtQpiJZsKa0m+o4bqMwBhm0OstWV9wXGFPVu1
1yswxyiDQKyBUcWaTNEFOzvJn2PlzLdYSlyrIFY1kK+CWAyQr4JAINBUEAg0FQQCTQWBQFNBLCuM
ZUnK8YOVpAyaCgKxguB+r8JfLhbPU8nvDtS8PPY7GpGA9hj+SVyJc9LwTQNqXln2EeuGVJ/OKU+u
R8G5tDFw/wGisKksGaqf8YBne6WaN746SewjfzkFBmkapfokyZPr7Jh2K+yvDfsfLQUxr6nw/pc1
GLG9yz6k/a3YG8YjnA6bnRl2eqv58mOrmzbmfT3ubaE8X64hGKqxFEN2mAWr8mW9UYb1wXJmMAp2
vSvOVPIZK84ht5mcCGc8sNpw7t5Ka25muDdhqlDYUF1zOsfa7ExqQcOat4qpLMdS5tDmwh1U1AVf
wGLm2suWYYVWfLA4w/cSU4y55lyq78xF9f6q89xpzyxp/k7GyDehHH1V35ugFr4IsEZIBCLfVFSr
2RnzW4+xtOF4QSueJWZZDCtF9X9KgUBTKdT01OJap7rAAdVYjFEUkWnuJIa6gFyLWQ4h1pypwJzP
jA3/ZYLqWgy4D/0aqLoAyzIWMNws1GRX4vLxfAzP6jLKXn5lzqOpeBgr9oSeHwoOi5fp4TozPKuC
IgghqvX0zFWCs1zxUGYKrdKLk2s4L1YKz6tshXm+C9WI5n1XVTjl8iy9jeJMwP0GbKVhUXwVQy1p
NS5NyoJv2hp4t5j/rqrg3DP/rVZxLV9djrvpfdh6oUzAFt89lPkiF/imcG0u1Iu4anVB4ozlsJSV
PYgv2FTUcl2vWvKETuq1Zy6lndKo57n8C8NUEBfqEn/+nn0ZR1x1IXOwlQncWbxWLGVNl4+mgijz
gmZN6ICmsqat4Dy3UuPCtxT3w2LDd6y03pMs8AlJ/v7gHAmuzb1+pfpyTayci+SnrLlVvLMDvPCy
2k5pLGiitIj3KmqRFqVeEO9VjEJMkQXWTK6p+HG+1DnKLcA18cgqNg9u40Is2wRM+Epx3Ky4XagY
Yhjw9baS72fFEuKOtOQayzvsookgSomC/lU8pMEc6grM4W3F2/A9zBc3v8XNGplrJjbPyF8kPwWB
WA5TmadjVr3N0OttpchWqfq1/vk8TuYcz/ku0VjEAguBWKipiK66+LWVUfhRRxHfyy+m18/ZNakW
lxgXKojlNRWHG7jgrTtG7ocdFuDXa87J1EKYJjiWzIM4/WcB3+fu2DVTGRsC6L7GhNsfCC1BUlKd
rfxpOznQth4K6MoFv6wXa/WijCTf24oB8w8sht+gojLMP/vylO+Xx5g7DwISBMWnbtgZyxwYNwHe
J50791jdEiSZtbF09IkGgIGpezK6Wn+hm4pqGOyDQfzH+XyGOM8/cx2rhqH6yMoVzOXyx2H0uViu
e2KR0shTBgqzVwrlwTlYwcFCCYVVCHeDGQYzGoqafJQgf3E1DJosKUk+FESHoD1SCzDdq2ljKT9J
ESlcC2ETuhUwY5JbUq0MmhTa3cHS1RJJQ08TqeuUdlCU1AVsKqrVVTs/qr18FudOf27ncMWoqljd
q+5kqlsCWHJVZ1xQ80cLyMmjzjfBmjsPIg/X6mZkCqQxeFGGumdNyT1enIWJCOn3+VjQQ/7pzQKE
GlUTMn6SfpIhZiW9CB+QIBjKPOua1j83AJM/Nvf9L3aSpZJ6iCGFe6nIzGqYgK1gLJAqgYOK32Il
Tjv9pAJ6K+z/PXguBKlN0Ovq5Hs1CJnJJA9p1ejiYhbgZyPpyO4GP0ntYLTCm8+B+SNqBdVhJ8G/
1SC4I5l83iuJH1SgqSyzrSxj6rWzViH/6jWzpE1f/jF4bAjaNE/LJS35ZzO160120qXTxCR2S8XU
my9N+EjqromRJXry62C2UyvYMuuRdDpas67BK6mTHQCaCuKCwMUVdYdJW66uTbJGrPMGbjXgLVMD
kVvZUaiJ/NNEJlWyDtrItI+kqyvINA60UI3MrECIsCRpU+diY+wo2Ez+aQ4BpJnIEJoK4oLAzD/3
7CQ/39xEev7U69BEhpjODn2DiFWSWsX/5XPYm+qh/qYIwJcadf2gX/ueDfXQ5ckzV5J/0wocSxOD
SDqSNO0MP4pMEkmTZAA6l+yAjuRvLqjqCijYZNYcGvvZT82rt0rr++HwvacfhOwPKsAIwMRTX5RJ
EE1Qu/NkdpTZReDkZKXZOwRw73e6bv/+SMBH0pZbHz3eD7fdd4pI0uD7UwH40lNHzwlJP+s/FY6x
h2lTP/9WIHvgKwBfHB869aTxyAVVa+hhGIHACRgCgaaCQKCpIBBoKggEmgoCgaaCQCDQVBAINBUE
Ak0FgUBTQSDQVBAINBUEAk0FgUCgqSAQaCoIBJoKAoGmgkCsfFOJE8iK+NyZCMpJnpQfdULjPvLi
8xcZx1pHXOijSiKRGJCr5/oIbU30s67kWH2ItTsB0/pmWL+flKQw/6RsbTX9V4/Iig7xtveyMDMs
vrU5oEjhgwAdISs1jeRf4uxW5FqSwvrCZ0041EHPJA0rHbEq1ipNPKQmljnAPo5Wa7JPOKlyWrmU
jCN8JFHPvsC/2vlpPaNcTwyhKnNg3JJQZ2SkuwGuCg/M0LMRU6ZpZ88mdpAz6dwwVjrigjcVulbJ
8I+bhe7tuJx+hlP9xGl2Hu5l35oVOKW1f5QdPK/QL3CClOm4PG1FpkNgfJnm0OiXbz4aAp2mPaG1
t5G4Xg0/UI+4IOH+uFE8AUn18BZ2YNaa7f9vCOJHt70QEnEQMtkPP5HT9EffcPNj21nqiqohEUWX
7Z0ZYj72WRdLS/9EIAJxoU/AFOUafhCaPHc3nYBNvspnWvRDnU5a0/rI5sWV3x3nqRX7W7adiUSC
WEQl/yBnFzmzBxy4Wb/QvlSLQPivVSz3ieGkJtOlBoxk2LwrpLBvzQpUw3GZHczwL3CGO7Qf2t+y
DZugRgGSTbCBLOTlAVAjTsYm/N42YpUs60+lWLdfpUo7DrGAA7UsuE5KnbITjd32DF+dj0zcRZ9o
xZ667okxK3K4dk+KGIeRlvcR6f3NUqrXznjPp/fgEzDEBb9WKTn23jqFNYxYfaZSvrfouK5H4KiC
QKyVtQoCgUBTQSDQVBAINJUc6GXPiEDkOLhTg5nu3sbGNwIQ467NIN7Y2LjrX0590SdnvP88qfxI
1r9sbapibg3/2j+jCMuNinGfbAhE/qiibzPgA+S3AeCUKrrgRCLxhcCnV5TK2/2fNutT2Xkytsz5
mDo3ytiKoxCigKk0dYXIJKUbDNJDS01Ob33iEEB9WKbv2eO1YZn86IpMHzJbXJRaeU8yuZvyUYBy
V2TKXRFxemS3GufvbOKM9RLtZhnkJGW9UCndETnCG6UeCR+M23yXeI0idbj5LkQHiegQZ/+RVG4e
DNU+GbJ4MyIP05DJMqnWIiPRIeLowBJZ7JuOSChMNOpgXJ3Qj5uweSD8TSWzHyACEtA52f6My4SC
ABMH0i2T5HjmbJT8XKoM0C1fwZAp0S1gMwP7tPVPUj4KtYiqNOWuCJ7KpcNPfsaRdOnP00NXsQwj
NWS+F67aRtL/PD3MX+6o0tkXwOa7AJwZjTt8l8BZokOG6CA4M3VBXjbnwRCkG2zeTF0Pz0NzZ2Qi
q1apmrIyXhpOy3FbB4rg2SGe+tphMzIFsCPKuDoNGWweCH9TyV4Oekun3rV9GOByQU6Jx+OSeRog
1Q5/2AqUdqKTH7NHo3vAbumD3lvI77A21NLH+CgEMueuCJ6KmdQecEowt4ASZlIUktjsG3reCQNQ
+lhawXeBfk1pd/guPZqtA8NHRdknrHKn37B5Mx9dz/MwWTqRle0dStk69ECvaevAplqawvc+JxWg
V/e5+5KUq/NGFpsHwoH7bX3IhOT13RO3v/7JP2R8FBAUlnGyxDcbsu3pRA7txOGt2H8kZW2msmrI
4qmETDulQ2Wxzjj5hYfx8n0Sgc13cXTILxuYToI34+RxyQJXRinjyugEdO+azm63uTpMHwTCZ1Sp
1OHtsCX+OtzhfrCq/IhaU83s89/2pGRcFD/2SWjyTeUqm6cS0EE0OIu84kxrulhmJ6ySp+30JnL4
Lh4d8squ0G3ejJNHyOpyJaUZvY/KGkC/mR28r0IS7BvK1dHxnROigKkEj8M07E98kvwLStAO3jlD
lr/ZoctdT4wpF4X8pJqhKZUrkXJXDto8FUkBuu7oSurU4ELdoDlPp0NN9bvdYamNcHenzXcRcPFd
hA683eeVHThu82bkBivP7VxWsLmBzPE6WcbQcTfzhmISlGo+hwv11PEroFyd40FsHgh/U5Fe100I
wifg42R4edYJH/0zHUar1n/T9SA1E95HB4q0lMkbVmJPSZS7IngqJ+plmm+klvFaTl0jfyzmSLlp
fB8PGxNS5W9W2HwXARffRejw0HpmN7lly202b6Z/ysrzAJc1MjVOzfYuGnTqA7KLecPkhuvvYQcH
J9bT+qjaxbg6bRI2D4T/WkX/+HNWd9vdPlA6CtYCyPRactHv/fSLxkOlrBmz6iyy0BD+pgKqPYl/
ZI9SujLkdHHpqtNQObb45q6aE6WsmVn8tgyioKkgEIhi1ioIBAJNBYFAU0EgLgBTWcbdt/r5VwGB
8DcVNUa3fEnRAbC5GlqcPjGNF/yey8VL+9LLXHkvEhrE5slz0ZyeXnKjHsEnwIglmwrlq0AiU731
0w5fJb1p7v21Lcv3qaLtXKmpU/OnWwANpWUKRyHEUk2F8lUIhuCQzVfRs/eYdtPSI5KiU58qlOjB
uR0WB0TJ4YCQNHtzfavwfCJM8F9ot3+QZNLCXm4KSR/nA0KTrBFtQgqJ1qOSzWxhvJcGRUoW5K+Q
8mjqOAieC2iypCRhi3QM7zpiEXAThgPP722Efqh/+2AaDj7Odjl+8O/+Mtz0LDT20/+/UDVZ/b8z
8HUpUjENf6dXVk9N9zcmaMxXwxNV385A45l//Ysa9u1ikuYH01AZnYqlK6Dx7Onf2TEt8qkGVIXT
MHPgG7f9wzQTPPns7qcDp3bHZ0D9zUM0jqenoqlSb4VgOjI1/v0sfGEKEu+uYOX97GtjeyugUhqp
yQoV1IC7LILGe05/7eEMjZo58E1a1kxksnpXD4z8EHkoiCWOKtnLaScfv+Llf7H5KrslkD5nxQsf
Kx/rI6YEKc7t4DB7uPcVmwPC09zi4ZTwMME/cXFP7tHaKdul3eGZ2BwUKpqMRA9nk8kUgBKCdm7Z
guOS6QvZOybz+CuURcMvQpQV1LWe5wGSH8O7jlgEcvgqcTK3T14vPy92o+g3zZIk39fymB5gcTvm
4IBADqfEoad0pb3cEx9uip2e6tH9/iwk2lh0hzkHDcXDX3F0EmXp75ierRnkxBYEYimjSiVfCChk
rSKewB5/KZFIHLHmaILpwfeyC26HJ8YBT+PllHTa9JR0Lv/FEuPxxWKtkAC2TJ2L7uDRpp3Qh4bi
zThgMU5EWdrUQOz38dkyogSmEjzOfuohaPFVdn+V/PM3Ddaow32sSE2mDDAdZJ5VCnBAeBovp4SH
Cf6Jl/8i4PBMROOnSjUTZTTtLBneUibs5WYrOC6hjWa4IH8FmuEy/oxBlLVb0+BxEox76xFLNRXp
dTpvkT589DRwvoqevYH8e0NWdMSn6uT0KQAjeesIwMHJ9XTuVoADYqRoGi+fhecT/BMv/0XA4ZlQ
cF7Ks1mAvqRUGyMCauTPcmaL4L38Jh07UJC/AiPKFN8bLMr6x2RokiiQfQbvOmKJa5Xl4qssCfpF
1Dtl6dB9NdJQEEs1leXiqywNycfuKKW42KCCdx2xVFNBIBDFrFUQCASaCgKBpoJArDpT0UuUBoE4
v6aixqBekfbMDtt8FcpfURp8CCvxObkmSanaN9zNbimU/eK5FV4CO0Zk1WZ94jr2VC9BZK5SMXwe
vbpNRd9mNIwFzj2y41K3f5VzYb6BJY8TMgdJpGZ0zDfczW4plL1luUc2Xz8sO1rGliATfbOsMVNp
6gr9t7awpiQm3f5VNGPWHkc4H0WPyAdFQI3gmexRecdqRqWYCfG261kOTeb8Fil8kPlLsaglzK8K
zd4hce6KJHy3SNwLiuCngCuvKEcS3XU8KXPvLZa/FkjKnNMSYWUKPzB2PsvfCnA/LEQzymVx+DHx
ticsXyxET8ah2ZtkeYXPFYdzs9cjzwzHPL5ZkuibZS2YSmY//Dm8wY9d/lVcXxm2/KIMvGCFnD1E
faAEvyB60TopE6yzPJnA8IBCWs+n9YxCTedLZ0Q496tCsfucVAfCbwr13RLj7lMmIqa+iyWw8opy
nj03LMptGAjVOf5anh6AGoXlUeW0cilYfmCsfLa/FeB+WCA7IF/qhAfO0lKJ7lQm0RPghYGDn11/
lvp32cV9rgg/Lu+Sq/+zR17w7PP8SKSriaFvljVgKtnLoRVEt+3yr/JeJwXnoyg92j0ioJ/zTPqt
LzGme6HP2Rusaz1hgOcVMCg15QZrAs/9qrCJitb70VzfLWDzU8DJK8rZZH/x8ZRGy7F8s2zSrDyC
U2PJ6vfwYBioHxYSTn2sWOE9mlt3quc9Wvv2PubfxeLleDg3jjxDa+fXK9KF7u1A3yyrEzl8lR2z
T4sGbftXgfrxtIsTQv4cnykigKbNJYk4J/qGmx/bnnCxUNw0E5rX67uF+jnh/BRqbJ68+eWAzVux
OC0JzrtJ5Lp1ETwYsHzDWNm9/BgX6Ub8ObycPM4NzOGbBUkxq3pUqdThZbhMDAhO8FBuHsdnij18
WOk7PawRnTFGLq787rgntUMz4anzuCuCnwJ5eR3pOvOJ4vLXYnFadB+/KB4eDPXDQvSnqbz8mE4/
bzFeXo6Xc8MmggV8s1Rg01rNphI8DiOdKb0jHvX4V1EDOXmSTVDvCZAbYUMnOwo3w8awHb6BkUNm
Qj2WsI5uNnoxvypMNDTJudwVkkbwU8CTl5azkbl14aI3Vnv8tYg8glPjhYcHQ/2wwN1kdZ/Lj/Hq
bs/Xgm4NBOfGyef4ZuHpwknmm+Uy9M2yqk1Feh1C1dl1O185BbZ/lXhcSo/mPgpNy96Ouz8rV/K+
dTi9xxy2w/fJ6RMA0Ym7rFWKzGZV3K8Ke2Ig0dRe7gpJI/gpBCNOXlqOKVtNMLAne4/HX8tPeZ5T
dVIq72tIHh4M0+E6+T4jlx/T79HdguDlWJfOeDiufI5vFp6uSmW+WTLIH1vVa5Wl8FXUzGRe2Lx+
VeKL/oTY4nMyPyzxxPLWKvpmWeWmsmi+ymx4JjSa7xhlXr8qi1/7LsWjqWpOFOvxZbFA3yyr3VQQ
CEQxaxUEAoGmgkCgqSAQq8pU9PNcjn6e9EGsErg/7w1qsK2x8cxne5IQEw+04uRcUqcg3k//dyEv
wINkNJr3jOmvy7QtSpRz+PsZoWeB8sm53xWIsNyoWS2FjQVHFbufZf5Vzu19b/1y8FVaynRFvBz9
AWOe8lsW5JYluw1HITQVG9y/itYDydLwVYQ/ljhLS/9j/lBsXkieXxWw+SkdIcr6yPGrwv2jkDiZ
xsVVSdbq9zB9eLzDdxHXIvQ0Y7Q8Gi7KYXwZyzOMh9/CLkGJcgaKrQstL9SFDBQ0FRuZ/exHhmxp
+CqqnGHcEdFNJyApT6pg80JeGDiozeTwSQQ/JV6VOUDGMsFbUUcyPyH5JiMZ5cM0Lk3jQD83ksp8
genD4x2+C/CdJULPOiMj3c3CRTmML2Pr6OW3kJAzLwS9urDypDQ2FjQVe5JxOTcNmCkNX8Xijji2
yPyhWGny/arY/BQp03F5OtevivCPIvM4MDRlm9BH+F2x+S70Wt6w9UyHwPgyCxTlOHyZPH4LUCZM
+y1uXUR5b0xjY1nb8PGvot9IuRil46v4EFVyeCEO/0PwU8xas6JqKMevivCPYtZmKklcTvYO00sp
oTpaeoJFavHwVhyVHH4LuH3C2Lqw8pCBgqOK65jPotLUaUQp+CqO1xXdDgA/XojD/xD8lNDkOWUi
16+K8I8SmnxTuSove+6eMHotQs9Om9Qiysl1y+J9YG5a2tm6sPKQgYKm4oD7V9HXwQul4asI7khX
UqdDV0e38IeSzwtx+B+CnxLu0H44netXRfhHoXEHPdkdvysAFieGXovQM2yCGmXhohzOlxHcmTx+
SzUcl3N1IeUdD2BjQVOxwP2rrPvcL9tLw1cR/lhGatfRh0tym/CHks8Lcfgfgp8Se+q6J8Zy/aoI
/yixp6QnvI+iHb8rABYnhl6L0HO4dk8qwsJFOZwvw9Pl81vGbruOaxe1dGHlvS5jY8G1ij2NKjFf
5XzCdS0lgfmhJ5GBgqbitPfS8lXOK9TSLi5m6/AVJJoKAoFY2FoFgUCgqSAQaCoIxIVoKvqiohaa
RXdH4YIbUe5lvWpyv9eJmMSbX9EfAXIS3vaVgomU5IKlebOo5oQTLqJIWnLkp6gIy42yrg2BWPSo
wvkqBEvxD/KrwlGLYKx4sjD97HARlVgo8wR9nyCWbCqcr0Lh8g8iOCqmQr2H6Ioc6ba4Iixc+FAh
6I5QnyWUBCL4I+CkB4ux4vFPQkTvSSZ3hzpsDgswdgl911cflvdoguQiCyoJ1c8OZ/JqZSGXM08i
3ba+TFQ46vF90oG+TxClMRXBV6Fw+QcRHBU5tg3gUiUdpu2ecUVYuPChQm3h5+lhldFALP6Ik150
7wnhnyQYMqUgE71PW/8k9VtSN5KR72ap6oLnKLN34kC6hZNPxqPp6IStnx3O+CZPDwi5tKxwWo7b
+lIEzw5xFsy13PfJjij6PkGUxFQYXyVO4PEPwjkhnONh9nB2h8MVgSzzoQKOrxOHP+Kkt8H9k9zS
B72UEzKsDVHGShvjlOiCU9KnnQDH5wo5GgK9zdbPCafY5NpsQsrqNW19gWvJ9ysnue+Tz92XRN8n
iFIs6wVfhYGzM+K5jkXyqSY238NLC+kw89N7xMjpXMpJJytScF8cnytmffbqtM1BccLjOS5bcnSb
w/fJUr7iisBRBWy+Cltk5G6g4hwPh4HidOYW36PLQwsxwZve4bOIYK8Uh1OS53OlBoaec/TL88Xi
1jBHt0K+T/BdEmKJpsL5Kgx5/kE4xyN0PM97SR008+3pwtdJp+nij4j0nZq+gdsJ90+SaoYm77eC
buecErB9qAifK6T9Zw8k6xz9nHDON3HsL183x/dJqIeKCHcw3yfH0fcJYommwvkqbK2S5x+EczxO
fUDO9V6yT773BDugvk7GAB6OufgjIn1s8i5KjJLuEv5J9LSU8Q4rD3BOCdg+VITPlYfWw+h31u9z
9HPC5TZb77tcZbng+D6ZWE+vs2oX833Shr5PEEtcqzgcj+L9gyy3pxI3SsNBQd8niCWbisPxKN4/
iFzOb/6UhIOCvk8QSzcVBAJRzFoFgUCgqSAQaCoIxAo3Fb0MOZaWD4EoGfL9qzQ29j/SzffmDn+1
IviVJx60onN9jhTwUDIHCuXQApnF5ENfKIjzM6pYfBVomeLd+CdC5wbu2lAw79w8kQXk0KdOLSqf
APpCQZTZVGy+yhbpGPs91Kdpo2m3/xPBKzGpNxLOEwl3kzMX34RySCw+CueyWP5UahTBLInXhDlH
RRZeWTZSvyiLyOcwUjx+WdAXCmKZTcXhq7z5e+xH2qA1QNrt/0TwSmqVqinBE5GuhbfJLr4JabZ2
es5lsfypfOmMYJbA7FnKUbk7NCB6f/PNxeUD9ewLfn5Z9qMvFMSymorFVwFIfowFnBxNjYYb3P5P
BK8k2ztkLQfezIL5IxffBPo0O73OuCyWP5Ub7P0kJxhH5ct91ntzM7m4fNQXip9flsvRFwqi5CjA
V7GdiehNyZTLL4lDSgFBFdHXp8MpF9+E8UXs9BaDJI+0Qv5oGVyQ5Z9lofl8fKEwvyzoCwWxvKOK
w1cRB7LOPUE6/k8Er8TloURL1SQ9fBNw0nPfJfn+VDhudsL1RebL94XC/LKgLxTE8pqKw1dp5vvU
5Q3dem2l2/+J4JUEmxvCFk/k0JV1br4JyyfSb2CCXP5UHI4JQfVGULt4wc2Ly+frC2UaGSmI5TYV
xlfhq5Zn+NoAvrn+/jNu/yeCVzIyNR6xeCKbOnvcfBMKK/0+OX3C40/F4ZhQWeYejTsvfja7uHww
dtszPIXXL8vryEhBLOtaxeaDdF9dEkrH/FwWNT3FCr7o8JbF5CsA9IWCWGZTsfkgsUGlFLLn4bLE
zNlQz3p2mHzsjkXl8wf6QkEst6kgEIhi1ioIBAJNBYFAU0EgVpCp4EIZscaRw1fJ1M9WfubXk4GY
5TC4I/rLUO1UYaZJAcoIArGaRxV9m9EwFjj3yJYPwSmVDyMNO/8+c2C8c17fKAmsScQaGlUeO5l9
IDl8b6i/Bx6MfJltHa5QhmFv9eNmHBr7G0dnAjVJ6H6yUn7zQYgbs3T/buMEBN96kI4qDbOBIIlO
xirln+3FikWs5lElsx/+HN7gx/v55sdsD/mnN8u5KdmB2KTlRwUov4Qi/a8x/mpG+EGpUUx9F9Yr
YlWbSvZymAWNM1Yu55zGVrpDRJvh8Sc06qXE8qPSxzeP9GuDfE+j8IPycDaZRGo7YnWbyowGFaDz
dYfGt7iw3faWlwVuG63ElGbtM6gj+diBWRPdTX5aZmrWdWK9Ila1qVTq8BCIjfji4fBDdHt8k2dP
e5eHmgL1liUJPyhbps5Fd2C9Ila1qQSPwx91XqezpYfCzeOPJuuhYSpicVMohB8VC0m4jM+3hB8U
RdPOzmK9Ila1qUivQ6hmZt3k0XsA3v4st4uqj0oTVYMWN4VC+FGx0KMkOdNd+EH5aVKqjWG9IlYd
/P2rQHf7AFI+EIgCpuLyX/LIHgXrBoEoZCoIBKKYtQoCgUBTQSDQVBAINBUEAk0FgUBTQSDQVBAI
NBUEAoGmgkCgqSAQaCoIBJoKAoGmgkCsQvx/6YrEnhU6KEcAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2016-07-12 17:05:22 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.03" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Corticosteroid (OS) versus placebo or no treatment (OO), outcome: 1.3 Motor synkinesis and crocodile tears.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAyoAAAFACAMAAABk53jgAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2016-07-12 17:05:22 +0100" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.04" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Incomplete recovery of facial motor function, outcome: 1.4 Adverse effects.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAyoAAAFACAMAAABk53jgAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-07-12 12:52:06 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2016-03-29 12:02:32 +0100" MODIFIED_BY="Ruth  Brassington" NO="1">
<TITLE MODIFIED="2016-03-29 12:02:32 +0100" MODIFIED_BY="Ruth  Brassington">Cochrane Neuromuscular Specialised Register (CRS) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-09-03 09:41:20 +0100" MODIFIED_BY="Angela A Gunn">
<P>#1 MeSH DESCRIPTOR Facial Nerve Diseases [REFERENCE] [STANDARD]<BR/>#2 MeSH DESCRIPTOR Bell Palsy [REFERENCE] [STANDARD]<BR/>#3 MeSH DESCRIPTOR Facial Paralysis [REFERENCE] [STANDARD]<BR/>#4 MeSH DESCRIPTOR Hemifacial Spasm [REFERENCE] [STANDARD]<BR/>#5 (((bell* or facial* or hemifacial* or cranial*) NEAR3 (pals* or paralys* or paresi* or spasm*))) AND (INREGISTER) [REFERENCE] [STANDARD]<BR/>#6 #1 or #2 or #3 or #4 or #5 [REFERENCE] [STANDARD]<BR/>#7 MeSH DESCRIPTOR Steroids [REFERENCE] [STANDARD]<BR/>#8 steroid or steroids [REFERENCE] [STANDARD]<BR/>#9 MeSH DESCRIPTOR Adrenal Cortex Hormones [REFERENCE] [STANDARD]<BR/>#10 MeSH DESCRIPTOR Adrenocorticotropic Hormone [REFERENCE] [STANDARD]<BR/>#11 MeSH DESCRIPTOR Prednisone [REFERENCE] [STANDARD]<BR/>#12 MeSH DESCRIPTOR Prednisolone [REFERENCE] [STANDARD]<BR/>#13 MeSH DESCRIPTOR Glucocorticoids [REFERENCE] [STANDARD]<BR/>#14 MeSH DESCRIPTOR Cortisone [REFERENCE] [STANDARD]<BR/>#15 corticosteroid* or adrenocorticotroph* or prednisone or prednisolone or glucocorticoid* or cortisone or methylprednisone [REFERENCE] [STANDARD]<BR/>#16 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 [REFERENCE] [STANDARD]<BR/>#17 #6 and #16 [REFERENCE] [STANDARD]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-07-12 12:51:57 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2016-03-04 12:01:15 +0000" MODIFIED_BY="Angela A Gunn">CENTRAL (CRSO) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-07-12 12:51:57 +0100" MODIFIED_BY="[Empty name]">
<P>Search run on Fri Mar 4 2016<BR/>
<BR/>#1 ((Bell or "Bell's" or Bells or facial or hemifacial or cranial) NEAR (palsy or palsies or paralysis or paresis or spasm or spasms)):TI,AB,KY 555<BR/>#2 (steroid* or corticosteroid* or adrenocorticotroph* or corticotropin or prednisone or prednisolone or glucocorticoid* or cortisone or methylprednisone or "adrenal cortex hormone*"):TI,AB,KY 37189<BR/>#3 (steroid* or corticosteroid* or adrenocorticotroph* or corticotropin or prednisone or prednisolone or glucocorticoid* or cortisone or methylprednisone or "adrenal cortex hormone*"):TI,AB,KY 37189<BR/>#4 #1 AND #2 98<BR/>#5 sr-neuromusc:cc 5823<BR/>#6 #4 not #5 44</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-07-12 12:52:00 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-11-14 14:24:27 +0000" MODIFIED_BY="Ruth Brassington">MEDLINE (OvidSP) strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-07-12 12:52:00 +0100" MODIFIED_BY="[Empty name]">
<P>Database: Ovid MEDLINE(R) &lt;1946 to February Week 4 2016&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 randomized controlled trial.pt. (407164)<BR/>2 controlled clinical trial.pt. (90097)<BR/>3 randomized.ab. (304430)<BR/>4 placebo.ab. (155333)<BR/>5 drug therapy.fs. (1823046)<BR/>6 randomly.ab. (215472)<BR/>7 trial.ab. (313777)<BR/>8 groups.ab. (1364056)<BR/>9 or/1-8 (3457470)<BR/>10 exp animals/ not humans.sh. (4191570)<BR/>11 9 not 10 (2944190)<BR/>12 facial nerve diseases/ (1409)<BR/>13 Bell Palsy/ (977)<BR/>14 Facial Paralysis/ or hemifacial spasm/ (11784)<BR/>15 ((bell$ or facial$ or hemifacial$ or cranial$) adj3 (pals$ or paralys$ or paresi$ or spasm$)).tw. (14759)<BR/>16 or/12-15 (19812)<BR/>17 steroid$.tw. or steroids/ (195309)<BR/>18 corticosteroid$.tw. or adrenal cortex hormones/ (111371)<BR/>19 adrenocorticotroph$.tw. or corticotropin/ (47991)<BR/>20 prednisone.tw. or prednisone/ (46046)<BR/>21 prednisolone.tw. or prednisolone/ (38861)<BR/>22 glucocorticoid$.tw. or glucocorticoids/ (87141)<BR/>23 cortisone.tw. or cortisone/ (22428)<BR/>24 methylprednisone.tw. (209)<BR/>25 or/17-24 (448308)<BR/>26 11 and 16 and 25 (892)<BR/>27 remove duplicates from 26 (886)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2016-07-12 12:52:06 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2011-11-14 14:24:39 +0000" MODIFIED_BY="Ruth Brassington">EMBASE (OvidSP) strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-07-12 12:52:06 +0100" MODIFIED_BY="[Empty name]">
<P>Database: Embase &lt;1980 to 2016 Week 09&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 crossover-procedure.sh. (46158)<BR/>2 double-blind procedure.sh. (126385)<BR/>3 single-blind procedure.sh. (21564)<BR/>4 randomized controlled trial.sh. (393423)<BR/>5 (random$ or crossover$ or cross over$ or placebo$ or (doubl$ adj blind$) or allocat$).tw,ot. (1223922)<BR/>6 trial.ti. (193286)<BR/>7 or/1-6 (1370827)<BR/>8 (animal/ or nonhuman/ or animal experiment/) and human/ (1446761)<BR/>9 animal/ or nonanimal/ or animal experiment/ (3498115)<BR/>10 9 not 8 (2901774)<BR/>11 7 not 10 (1261401)<BR/>12 limit 11 to embase (1041826)<BR/>13 exp facial nerve paralysis/ (20154)<BR/>14 Bell palsy/ (2578)<BR/>15 hemifacial spasm/ (2209)<BR/>16 ((bell$ or facial$ or hemifacial$ or cranial$) adj3 (pals$ or paralys$ or paresi$ or spasm$)).tw. (18906)<BR/>17 or/13-16 (28552)<BR/>18 corticosteroid/ or corticosteroid$.tw. (233317)<BR/>19 glucocorticoid/ or glucocorticoid$.tw. (101570)<BR/>20 corticotropin/ or corticotrophin$.tw. (58083)<BR/>21 prednisolone/ or prednisolone.tw. (106302)<BR/>22 prednisone/ or prednisone.tw. (142280)<BR/>23 or/18-22 (552861)<BR/>24 12 and 17 and 23 (133)<BR/>25 remove duplicates from 24 (131)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2014-10-07 12:38:57 +0100" MODIFIED_BY="Angela A Gunn" NO="5">
<TITLE MODIFIED="2012-11-05 16:45:41 +0000" MODIFIED_BY="Ruth Brassington">LILACS IAHx strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-10-07 12:38:57 +0100" MODIFIED_BY="Angela A Gunn">
<P>("Bell palsy" or "paralisis de Bell" or "paralisia de Bell" or "facial paralysis" or "paralisis facial" or "paralisia facial" or "hemifacial spasm" or "espasmo hemifacial") and (MH:D06.472.040$ or steroids or esteroides or cortisone or cortisona or corticoesteroides or corticosteroides or corticosteroid$ or glucocorticoid$ or prednisolone or prednisolona or prednisone or prednisona or methylprednisone) and ((PT:"Randomized Controlled Trial" or "Randomized Controlled trial" or "Ensayo Clínico Controlado Aleatorio" or "Ensaio Clínico Controlado Aleatório" or PT:"Controlled Clinical Trial" or "Ensayo Clínico Controlado" or "Ensaio Clínico Controlado" or "Random allocation" or "Distribución Aleatoria" or "Distribuição Aleatória" or randon$ or Randomized or randomly or "double blind" or "duplo-cego" or "duplo-cego" or "single blind" or "simples-cego" or "simples cego" or placebo$ or trial or groups) AND NOT (B01.050$ AND NOT (humans or humanos or humanos)))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2016-07-12 10:35:28 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2016-07-12 10:35:21 +0100" MODIFIED_BY="[Empty name]">Clinical trials registries search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2016-07-12 10:35:28 +0100" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov and World Health Organization International Clinical trials Registry</P>
<P>Bell's palsy</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2009-04-21 19:28:39 +0100" MODIFIED_BY="[Empty name]">

<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 studies from the previous review:&lt;/p&gt;&lt;ul&gt;&lt;li&gt;6 studies (previously listed as 8 studies&lt;sup&gt;1&lt;/sup&gt;) included in the previous review &lt;/li&gt;&lt;li&gt;1 excluded study reassesssed and included in this update&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;21 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;863 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;970 records identified through database searching (&lt;i&gt;Since the review was last published in 2010&lt;/i&gt;)&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;842 records excluded&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;14 full-text articles excluded, with reasons&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_z1305211200234164391015338304569_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="z1305211200234164391015338304569"><ADDRESS><DEPARTMENT>Centre for Primary Care and Population Research, Division of Clinical and Population Sciences and Education</DEPARTMENT><ORGANISATION>University of Dundee</ORGANISATION><ADDRESS_1>Mackenzie Buildiing</ADDRESS_1><ADDRESS_2>Kirsty Semple Way</ADDRESS_2><CITY>Dundee</CITY><ZIP>DD2 4BF</ZIP><REGION>Tayside, Scotland</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0) 7703 473 808</PHONE_1></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>